WO2022002100A1 - 新型苯并咪唑化合物 - Google Patents

新型苯并咪唑化合物 Download PDF

Info

Publication number
WO2022002100A1
WO2022002100A1 PCT/CN2021/103366 CN2021103366W WO2022002100A1 WO 2022002100 A1 WO2022002100 A1 WO 2022002100A1 CN 2021103366 W CN2021103366 W CN 2021103366W WO 2022002100 A1 WO2022002100 A1 WO 2022002100A1
Authority
WO
WIPO (PCT)
Prior art keywords
membered
heterocycloalkyl
alkyl
pharmaceutically acceptable
general formula
Prior art date
Application number
PCT/CN2021/103366
Other languages
English (en)
French (fr)
Inventor
谢雨礼
吴应鸣
钱立晖
樊后兴
Original Assignee
微境生物医药科技(上海)有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 微境生物医药科技(上海)有限公司 filed Critical 微境生物医药科技(上海)有限公司
Priority to CN202180046799.6A priority Critical patent/CN115867542A/zh
Publication of WO2022002100A1 publication Critical patent/WO2022002100A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems

Definitions

  • the invention belongs to the field of medicinal chemistry, and more particularly, to a class of benzimidazole compounds, a preparation method thereof, and the use of such compounds as EGFR inhibitors in the preparation of antitumor drugs.
  • Lung cancer is one of the common malignant tumors.
  • the number of new lung cancer cases in the world is about 1.6 million every year, and the deaths caused by lung cancer are about 1.4 million every year.
  • NSCLC non-small cell lung cancer
  • NSCLC accounts for about 80%-85% of the total number of lung cancers (Nature, 2018, 553, 446-454).
  • the EGFR protein family is a class of protein kinases that are responsible for transducing mitogenic signals and play an important role in growth and development. Analysis and research of a large number of in vitro tumor cells, animal models and human tumor samples have shown that mutations in EGFR family proteins lead to the development of human tumors and are one of the important triggers for the occurrence and development of various cancers. Therefore, targeting and inhibiting the activity of EGFR mutant proteins is an important means to treat related tumors.
  • EGFR gene mutations can be found in about 12 to 47 percent of non-small cell lung cancers.
  • the two most common EGFR gene mutations are deletion in exon 19 (del19) and L858 missense mutation in exon 21. These two types of mutations lead to sustained ligand-independent activation of the EGFR protein.
  • NSCLC patients with EGFR protein Del19 or L858R mutation are more sensitive to targeted therapy with EGFR protein kinase inhibitor (EGFRTKI) such as erlotinib, gefitinib, afatinib or osimertinib, they can achieve higher clinical outcomes (around 60-85%) ) objective response rate (ORR), but this response is usually not long-lasting, and most patients on first- or second-generation EGFR TKIs experience disease progression at about 11 months.
  • Drug resistance analysis showed that in approximately 50-70% of drug-resistant patients, the molecular mechanism of drug resistance was the acquisition of a second mutation in the EGFR gene, called the T790M mutation (T790M+) (CancerDiscov. 2012, 2, 872-5). This secondary mutation renders first- and second-generation EGFR TKIs inactive against mutant tumor cells.
  • Osimertinib a third-generation covalent EGFR TKI, was developed to treat tumors with EGFR del19 and L858R mutations with or without the T790M mutation.
  • osimertinib has a high response rate for resistance caused by the T790M mutation, however, about 70% of patients eventually develop resistance, and the disease progresses again after about 10 months (Lung Cancer. 2017, 108, 228- 231).
  • Molecular mechanisms of resistance to third-generation EGFR TKIs have shown that in approximately 20-40% of patients who undergo osimertinib treatment and relapse, a major resistance mechanism is the acquisition of a third mutation in the EGFR gene, the C797S mutation.
  • the EGFR del19/L858R T790M C797S mutant is a newly emerged EGFR mutant after the third-generation EGFR TKI treatment, and there are not many studies at present. Only a few fourth-generation EGFR TKIs have been reported to inhibit the EGFR del19/L858R T790M C797S mutant. For example, Boehringer Ingelheim reported a class of macrocyclic compounds BI-4020 with anti-EGFR del19/L858R T790M C797S mutant activity and in vivo anti-tumor activity (J Med Chem. 2019, 62, 10272-10293).
  • the present invention aims to provide a compound represented by the general formula (1) or its various isomers, various crystal forms, pharmaceutically acceptable salts, hydrates or solvates:
  • R 1 is (C3-C6) alkyl, (C3-C6) cycloalkyl or (4-7 members) heterocycloalkyl, wherein the (C3-C6) alkyl, (C3-C6) cycloalkyl , (4-7 membered) heterocycloalkyl are each independently optionally substituted with one or more of the following groups: -H, -OH, halogen, (C1-C6)alkyl and (C1-C6)alkoxy ;
  • R 2 is -H or halogen
  • R 3 is -H, halogen, -CN, -NH 2 , -NR 3a R 3b , (C1-C4)alkyl, (C1-C4)haloalkyl, (C2-C4)alkenyl, or (C2-C4) alkynyl;
  • R 4 is phenyl, (5-6-membered) heteroaryl or 9-membered heteroaryl, wherein each of the phenyl, (5-6-membered) heteroaryl or 9-membered heteroaryl is independently optionally substituted by 1 Substituted with or more of the following groups: -H, halogen, -OH, -CN, (C1-C6)alkyl, (C3-C6)cycloalkyl, (C1-C6)haloalkyl, -O-(C1- C6) alkyl, -O-(C3-C6)cycloalkyl, -O-(C1-C6)haloalkyl, -NR 4a R 4b , -C(O)NHR 4a R 4b and -(CH 2 ) m NR 4a R 4b ;
  • R 5 is -(CH 2 ) n -(3-11 membered) heterocycloalkyl, -O-(CH 2 ) m -(4-9 membered) heterocycloalkyl, - O-(CH 2 ) m -NR 5a R 5b , (C1-C6)alkoxy or (C1-C6)haloalkoxy, wherein each of the (3-11 membered) heterocycloalkyl groups is independently controlled by 1 or Multiple substitutions of the following groups: -R 5c , -(CH 2 ) m -NR 5a R 5b , -N(R 4a )-(CH 2 ) m -NR 5a R 5b , -O-(CH 2 ) m - NR 5a R 5b and -O-(CH 2 ) m -OR 5a , and wherein said (4-9 membered) heterocycloalkyl, (C1-C6) alk
  • R 5 is -H, halogen, -(CH 2 ) n -(3-11 membered) heterocycloalkyl, -O-(CH 2 ) m -(4-9 membered) heterocycle Alkyl, -O-(CH 2 ) m -NR 5a R 5b , (C1-C6)alkoxy, (C1-C6) haloalkoxy, -NR 5a R 5b , -N(R 4a )-(CH 2 ) m- NR 5a R 5b or (C1-C6) alkyl, wherein the (3-11 membered) heterocycloalkyl groups are each independently optionally substituted with one or more of the following groups: (C1-C4) Alkyl, (C1-C4)alkoxy, (C3-C6)cycloalkyl, -NR 5a R 5b , -(CH 2 ) m -NR 5a R 5b , -
  • R 6 is -H, halogen, -(CH 2 ) n -(3-11 membered) heterocycloalkyl, -O-(CH 2 ) m -(4-9 membered) heterocycloalkyl, -O-( CH 2 ) m -NR 5a R 5b , (C1-C6)alkoxy, (C1-C6) haloalkoxy, -NR 5a R 5b , -N(R 4a )-(CH 2 ) m -NR 5a R 5b or (C1-C6) alkyl, wherein each of the (3-11 membered) heterocycloalkyl groups is independently optionally substituted with one or more of the following groups: (C1-C4) alkyl, (C1-C4) ) alkoxy, (C3-C6) cycloalkyl, -NR 5a R 5b , -(CH 2 ) m -NR 5a R 5b , -(CH
  • R 7 is -H or halogen
  • R 3a and R 3b are each independently -H or (C1-C4)alkyl
  • R 4a and R 4b are each independently -H or (C1-C6)alkyl
  • R 5a and R 5b are each independently -H, (C1-C6) alkyl or (C3-C6) cycloalkyl, or the N atoms to which R 5a and R 5b are attached can together form a (3-11 member) Heterocycloalkyl, each of which is independently optionally substituted with one or more of the following groups: -H, -(C1-C6)alkyl and halogen;
  • R 5c is (3-11 membered) heterocycloalkyl, each of which is independently optionally substituted by one or more of the following groups: -H, -(C1-C6)alkyl, -(C1- C6) cycloalkyl, halogen, and -CD 3;
  • n is an integer of 1 or 2;
  • n is an integer of 0, 1 or 2.
  • R 1 is (C3-C6) alkyl, (C3-C6) cycloalkyl or (4-7 membered) heterocycloalkyl, wherein the The (C3-C6) alkyl group, (C3-C6) cycloalkyl group, and (4-7 membered) heterocycloalkyl group are each independently optionally substituted by one or more of the following groups: -H, -OH, - F, -CH 3 and -OCH 3.
  • R 1 is:
  • R 2 is -H or -F.
  • R 3 is -H, -F, -CN, -NH 2 , -N(CH 3 ) 2 , -CH 3 , -CH 2 CH 3 , -CF 3 , -CHF 2 or -C ⁇ CH.
  • R 4 is phenyl, (5-6-membered) heteroaryl or 9-membered heteroaryl, wherein the phenyl, (5-6-membered) ) heteroaryl or 9-membered heteroaryl are each independently optionally substituted with one or more of the following groups: -H, -F, -Cl, -OH, -CN, -CH 3 , -OCH 3 , -N (CH 3 ) 2 , and -NH 2 .
  • R 4 is:
  • R 2 is -H
  • R 5 is (4-10 membered) heterocycloalkyl, -(CH 2 )-(4-10 membered) Heterocycloalkyl, -O-(CH 2 )-(4-9 membered) heterocycloalkyl, -O-(CH 2 ) 2 -(4-9 membered) heterocycloalkyl, -O-(CH 2 ) 2 -N(CH 3 ) 2 , -O-(CH 2 ) 2 -N(CH 2 CH 3 ) 2 or -OCH 3
  • the (4-10 membered) heterocycloalkyl is:
  • the (4-10 membered) heterocycloalkyl groups are each independently substituted with one or more of the following groups: and wherein the (4-9 membered) heterocycloalkyl is:
  • the (4-9 membered) heterocycloalkyl groups are each independently substituted with one or more of the following groups: -H
  • R 2 is -H
  • R 5 is: -OCH 3 , -O-(CH 2 ) 2 -N(CH 3 ) 2 , -O -(CH 2 ) 2 -N(CH 2 CH 3 ) 2 ,
  • R 2 is -F
  • R 5 is -H, -F, -Cl, (4-10 membered) heterocycloalkyl, -(CH 2 )-(4-10 membered) heterocycloalkyl, -O-(CH 2 )-(4-9 membered) heterocycloalkyl, -O-(CH 2 ) 2 -(4-9 membered) heterocycle Alkyl, -O-(CH 2 ) 2 -N(CH 3 ) 2 , -O-(CH 2 ) 2 -N(CH 2 CH 3 ) 2 , -OCH 3 , -N(CH 2 CH 3 ) 2 , -NH-(CH 2 ) 2 -N(CH 3 ) 2 , -N(CH 3 )-(CH 2 ) 2 -N(CH 3 ) 2 or (C1-C6) alkyl, wherein (4 -10-membered) heterocycloal
  • R 2 is -F
  • R 5 is: -H, -F, -Cl, -OCH 3 , -N(CH 3 ) 2 , - O-(CH 2 ) 2 -N(CH 3 ) 2 , -O-(CH 2 ) 2 -N(CH 2 CH 3 ) 2 , -N(CH 2 CH 3 ) 2 , -NH-(CH 2 ) 2 -N(CH 3 ) 2 , -N(CH 3 )-(CH 2 ) 2 -N(CH 3 ) 2 ,
  • R 6 is -H, -F, -Cl, (4-10 membered) heterocycloalkyl, -(CH 2 )-(4-10 membered) heterocycloalkyl, -O-(CH 2 )-(4-9 membered) heterocycloalkyl, -O-(CH 2 ) 2 -(4-9 membered) heterocycloalkyl, -O-( CH 2 ) 2 -N(CH 3 ) 2 , -O-(CH 2 ) 2 -N(CH 2 CH 3 ) 2 , -OCH 3 , -N(CH 2 CH 3 ) 2 , -NH-(CH 2 ) 2 -N(CH 3 ) 2 , -N(CH 3 )-(CH 2 ) 2 -N(CH 3 ) 2 or (C1-C6) alkyl, wherein the (4-10 membered) heterocycloalkane
  • the base is: The (4-10 membered) heterocycloalkan
  • the (4-9 membered) heterocycloalkyl groups are each independently optionally substituted with one or more of the following groups: -H, -F, -CH 3 , -CN, -OH, -OCH 3 and -N (CH 3) 2.
  • R 6 is: -H, -F, -Cl, -OCH 3 , -N(CH 3 ) 2 , -O-(CH 2 ) 2 -N(CH 3 ) 2 , -O-(CH 2 ) 2 -N(CH 2 CH 3 ) 2 , -N(CH 2 CH 3 ) 2 , -NH-(CH 2 ) 2 -N(CH 3 ) 2 , -N(CH 3 )-(CH 2 ) 2 -N(CH 3 ) 2 ,
  • R 7 is -H, -F or -Cl.
  • representative compounds of the present invention have one of the following structures:
  • Another object of the present invention is to provide a pharmaceutical composition, which contains a pharmaceutically acceptable carrier, diluent and/or excipient, and the compound of the general formula (1) of the present invention, or each of its isomers, Each crystal form, pharmaceutically acceptable salt, hydrate or solvate is used as the active ingredient.
  • Another object of the present invention provides the compound represented by the general formula (1), or each isomer, each crystal form, pharmaceutically acceptable salt, hydrate or solvate or the above-mentioned pharmaceutical composition of the present invention Use in the preparation of medicines for treating, regulating or preventing diseases related to EGFR mutation.
  • the disease associated with EGFR mutation may be cancer; wherein the cancer is, for example, blood cancer or solid tumor, preferably non-small cell lung cancer, head and neck cancer, breast cancer, kidney cancer, pancreatic cancer, cervical cancer, esophageal cancer, pancreas cancer Cancer, prostate cancer, bladder cancer, colorectal cancer, ovarian cancer, gastric cancer, brain malignancies including glioblastoma, etc., or any combination thereof.
  • Another object of the present invention also provides a method for treating, regulating or preventing EGFR mutation-related diseases, comprising administering to a subject a therapeutically effective amount of the compound represented by the general formula (1) of the present invention, or each isomer thereof body, various crystal forms, pharmaceutically acceptable salts, hydrates or solvates or the above-mentioned pharmaceutical compositions.
  • the inventors found that in the compound of general formula (1), when R 2 , R 5 or R 6 is a group as defined above, the compound unexpectedly It has strong EGFR del19/T790M/C797S and EGFR L858R/T790M/C797S inhibitory activities, and has high selectivity for wild-type EGFR WT.
  • the compounds of general formula (1) described above can be synthesized using standard synthetic techniques or well-known techniques combined with methods incorporated herein.
  • the solvents, temperatures and other reaction conditions mentioned herein may vary. Starting materials for the synthesis of compounds can be obtained synthetically or from commercial sources.
  • the compounds described herein are according to methods well known in the art.
  • the conditions of the method such as reactants, solvent, base, amount of the compound used, reaction temperature, time required for the reaction and the like are not limited to the following explanations.
  • the compounds of the present invention can also be conveniently prepared by optionally combining various synthetic methods described in this specification or known in the art, and such combinations can be easily carried out by those skilled in the art to which the present invention belongs.
  • the present invention also provides a method for preparing the compound represented by the general formula (1), wherein the compound of the general formula (1) can be prepared by using the following general reaction scheme 1 or general reaction scheme 2:
  • Embodiments of compounds of general formula (1) can be prepared according to general reaction scheme 1, wherein R 1 , R 3 , R 4 , R 5 , R 6 and R 7 are as defined above, X represents bromine or chlorine, B represents boronic acid, borate or trifluoroborate.
  • R 1 , R 3 , R 4 , R 5 , R 6 and R 7 are as defined above, X represents bromine or chlorine, B represents boronic acid, borate or trifluoroborate.
  • compound 1-1 and R 4 -B undergo coupling reaction to generate compound 1-2, compound 1-2 generates intermediate 1-3 through hydrolysis reaction, and compound 1-4 generates compound through reduction reaction 1-5, compound 1-5 undergoes ring closure reaction to generate intermediate 1-6, and intermediate 1-6 is coupled and condensed with intermediate 1-3 to obtain target compound 1-7.
  • Compounds of general formula (1) can also be prepared according to general reaction scheme 2, wherein R 1 , R 3 , R 4 , R 5 , R 6 and R 7 are as defined above, X represents bromine or chlorine, and B represents boronic acid, boronic acid ester or trifluoroborate.
  • R 1 , R 3 , R 4 , R 5 , R 6 and R 7 are as defined above, X represents bromine or chlorine, and B represents boronic acid, boronic acid ester or trifluoroborate.
  • compound 2-1 and R 4 -B undergo a coupling reaction to generate compound 2-2
  • compound 2-2 generates intermediate 2-3 through hydrolysis reaction
  • compound 2-4 generates compound through reduction reaction 2-5
  • compound 2-5 undergoes ring closure reaction to generate intermediate 2-6
  • intermediate 2-6 is coupled and condensed with intermediate 2-3 to obtain target compound 2-7.
  • “Pharmaceutically acceptable” as used herein refers to a substance, such as a carrier or diluent, that does not abolish the biological activity or properties of the compound and is relatively non-toxic, ie, administered to a subject, does not cause undesired biological effects or Interacts in a detrimental manner with any of the components it contains.
  • pharmaceutically acceptable salt refers to a compound in which it exists in a form that does not cause significant irritation to the administered organism and that does not abrogate the biological activity and properties of the compound.
  • pharmaceutically acceptable salts are obtained by reacting a compound of general formula (1) with an acid such as hydrochloric acid, hydrobromic acid, hydrofluoric acid, sulfuric acid, phosphoric acid, nitric acid, phosphoric acid and other inorganic acids, formic acid, acetic acid, etc.
  • propionic acid oxalic acid, trifluoroacetic acid, malonic acid, succinic acid, fumaric acid, maleic acid, lactic acid, malic acid, tartaric acid, citric acid, picric acid, methanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid and other organic acids and acidic amino acids such as aspartic acid and glutamic acid.
  • references to pharmaceutically acceptable salts include solvent addition forms or crystalline forms, especially solvates or polymorphs.
  • Solvates contain stoichiometric or non-stoichiometric amounts of solvent and are selectively formed during crystallization with pharmaceutically acceptable solvents such as water, ethanol, and the like. Hydrates are formed when the solvent is water, or alcoholates are formed when the solvent is ethanol.
  • Solvates of compounds of general formula (1) are conveniently prepared or formed according to the methods described herein.
  • the hydrate of the compound of general formula (1) is conveniently prepared by recrystallization from a mixed solvent of water/organic solvent.
  • the organic solvent used includes, but is not limited to, tetrahydrofuran, acetone, ethanol or methanol.
  • the compounds mentioned herein can exist in unsolvated as well as solvated forms. In sum, the solvated forms are considered equivalent to the unsolvated forms for the purposes of the compounds and methods provided herein.
  • compounds of general formula (1) are prepared in various forms including, but not limited to, amorphous, comminuted and nano-particle size forms.
  • the compound of the general formula (1) includes a crystalline form and can also be a polymorph.
  • Polymorphs include different lattice arrangements of the same elemental composition of a compound. Polymorphs usually have different X-ray diffraction patterns, infrared spectra, melting points, density, hardness, crystal form, optical and electrical properties, stability and solubility. Different factors such as recrystallization solvent, crystallization rate and storage temperature may cause a single crystal form to dominate.
  • compounds of general formula (1) may exist in chiral centers and/or axial chirality and are thus available as racemates, racemic mixtures, single enantiomers, diastereomeric compounds and single diastereomeric compounds Enantiomeric forms, and cis-trans isomers occur.
  • Each chiral center or axial chirality will independently produce two optical isomers, and all possible optical isomers and diastereomeric mixtures, as well as pure or partially pure compounds, are included within the scope of the present invention.
  • the present invention is meant to include all such isomeric forms of these compounds.
  • the compounds of the present invention may contain unnatural proportions of atomic isotopes at one or more of the atoms that constitute the compound.
  • compounds can be labeled with radioisotopes, such as tritium ( 3 H), iodine-125 ( 125 I), and C-14 ( 14 C).
  • a deuterated compound can be formed by replacing a hydrogen atom with deuterium, and the bond formed by deuterium and carbon is stronger than the bond formed by ordinary hydrogen and carbon. It has the advantages of stability, enhanced efficacy, and prolonged half-life of drugs in vivo. All alterations in the isotopic composition of the compounds of the present invention, whether radioactive or not, are included within the scope of the present invention.
  • alkyl refers to saturated aliphatic hydrocarbon groups, including straight and branched chain groups of 1 to 6 carbon atoms. Preference is given to lower alkyl groups containing 1 to 4 carbon atoms, such as methyl, ethyl, propyl, 2-propyl, n-butyl, isobutyl, tert-butyl.
  • alkyl includes unsubstituted and substituted alkyl groups, especially alkyl groups substituted with one or more halogens.
  • Preferred alkyl groups are selected from CH 3, CH 3 CH 2, CF 3, CHF 2, CF 3 CH 2, CF 3 (CH 3) CH, i Pr, n Pr, i Bu, n Bu or t Bu.
  • alkenyl refers to an unsaturated aliphatic hydrocarbon group containing a carbon-carbon double bond, including straight or branched chain groups of 1 to 14 carbon atoms. Preference is given to lower alkenyl groups containing 1 to 4 carbon atoms, such as vinyl, 1-propenyl, 1-butenyl or 2-methpropenyl.
  • alkynyl refers to an unsaturated aliphatic hydrocarbon group containing a carbon-carbon triple bond, including straight and branched chain groups of 1 to 14 carbon atoms. Lower alkynyl groups containing 1 to 4 carbon atoms, such as ethynyl, 1-propynyl or 1-butynyl, are preferred.
  • cycloalkyl refers to a 3- to 14-membered all-carbon monocyclic aliphatic hydrocarbon group in which one or more of the rings may contain one or more double bonds, but none of the rings have a fully conjugated pi-electron system .
  • cyclopropyl, cyclobutyl, cyclopentyl, cyclohexane, cyclohexadiene, and the like are examples of the rings.
  • alkoxy refers to an alkyl group bonded to the remainder of the molecule through an ether oxygen atom.
  • Representative alkoxy groups are alkoxy groups having 1 to 6 carbon atoms, such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, sec-butoxy and tert-butoxy.
  • alkoxy includes unsubstituted and substituted alkoxy, especially alkoxy substituted with one or more halogens.
  • Preferred alkoxy groups are selected from OCH 3, OCF 3, CHF 2 O, CF 3 CH 2 O, i- PrO, n- PrO, i- BuO, n- BuO or t- BuO.
  • aryl refers to a hydrocarbon aromatic group that is monocyclic or polycyclic, eg, a monocyclic aryl ring fused with one or more carbocyclic aromatic groups.
  • aryl groups include, but are not limited to, phenyl, naphthyl, and phenanthryl.
  • arylene refers to a divalent aryl group as defined above.
  • arylene groups include, but are not limited to, phenylene, naphthylene, and phenanthrene.
  • heteroaryl refers to an aromatic group containing one or more heteroatoms (O, S, or N), which is monocyclic or polycyclic.
  • a monocyclic heteroaryl ring is fused with one or more carbocyclic aromatic groups or other monocyclic heterocycloalkyl groups.
  • heteroaryl groups include, but are not limited to, pyridyl, pyridazinyl, imidazolyl, pyrimidinyl, pyrazolyl, triazolyl, pyrazinyl, quinolinyl, isoquinolinyl, furyl, thienyl, Isoxazolyl, thiazolyl, oxazolyl, isothiazolyl, pyrrolyl, indolyl, benzimidazolyl, benzofuranyl, benzothiazolyl, benzothienyl, benzoxazolyl, benzene pyridyl, pyrrolopyrimidyl, 1H-pyrro[3,2-b]pyridyl, 1H-pyrro[2,3-c]pyridyl, 1H-pyrro[3,2-c]pyridyl, 1H- Pyrro[2,3-b]pyridyl,
  • heterocycloalkyl refers to a non-aromatic ring or ring system, which may optionally contain one or more alkenylene groups as part of the ring structure, having at least one independently selected from boron, phosphorus , nitrogen, sulfur, oxygen and phosphorus heteroatom ring members.
  • Heterocycloalkyl groups may include monocyclic, bicyclic, spirocyclic, or polycyclic (eg, having two fused or bridged rings) ring systems.
  • a heterocycloalkyl group is a monocyclic group having 1, 2, or 3 heteroatoms independently selected from nitrogen, sulfur, and oxygen.
  • the ring-forming carbon atoms and heteroatoms of heterocycloalkyl groups can be optionally oxidized to form oxo or sulfide groups or other oxidized bonds (eg C(O), S(O), C(S) or S(O) 2, N-oxide, etc.), or the nitrogen atom can be quaternized.
  • a heterocycloalkyl group can be attached via a ring carbon atom or a ring heteroatom.
  • the heterocycloalkyl group contains 0 to 3 double bonds.
  • the heterocycloalkyl group contains 0 to 2 double bonds.
  • heterocycloalkyl moieties having one or more aromatic rings fused to (ie, sharing a bond with) the heterocycloalkyl ring, such as piperidine, morpholine, azacyclotriene, etc. benzo or thienyl derivatives.
  • a heterocycloalkyl group containing a fused aromatic ring can be attached via any ring-forming atom, including a ring-forming atom of a fused aromatic ring.
  • heterocycloalkyl examples include azetidine, azepanyl, dihydrobenzofuranyl, dihydrofuranyl, dihydropyranyl, N-morpholinyl, 3-oxa-9- Azaspiro[5.5]undecyl, 1-oxa-8-azaspiro[4.5]decyl, piperidinyl, piperazinyl, oxopiperazinyl, pyranyl, pyrrolidinyl, Quininyl, tetrahydrofuranyl, tetrahydropyranyl, 1,2,3,4-tetrahydroquinolinyl, scopolamine, 4,5,6,7-tetrahydrothiazolo[5,4-c] Pyridyl, 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine, N-methylpiperidinyl, tetrahydroimidazolyl, pyrazolidine, butyrolactamy
  • halogen refers to fluorine, chlorine, bromine or iodine.
  • halo or halogen-substituted appearing before a group name indicates that the group is partially or fully halogenated, that is, substituted with F, Cl, Br or I in any combination, preferably replaced by F or Cl.
  • Substituent "-O-CH 2 -O-" means that two oxygen atoms in the substituent are connected to two adjacent carbon atoms of heterocycloalkyl, aryl or heteroaryl, such as:
  • linking group When the number of a linking group is 0, such as -(CH 2 ) 0 -, it means that the linking group is a single bond.
  • acceptable refers to a formulation component or active ingredient that does not have undue deleterious effects on the health of the general target of treatment.
  • treatment include alleviating, inhibiting or ameliorating the symptoms or conditions of a disease; inhibiting the development of complications; ameliorating or preventing the underlying metabolic syndrome; inhibiting the development of a disease or symptom, such as controlling the development of a disease or condition; alleviating a disease or symptom; reducing a disease or symptom; alleviating complications caused by a disease or symptom, or preventing or treating symptoms caused by a disease or symptom.
  • a compound or pharmaceutical composition when administered, results in amelioration, especially improvement in severity, delay in onset, slow progression, or reduction in duration of a disease, symptom or condition. Whether fixed or temporary, continuous or intermittent, the conditions attributable to or associated with the administration.
  • Active ingredient refers to the compound represented by the general formula (1), and the pharmaceutically acceptable inorganic or organic salts of the compound of the general formula (1).
  • the compounds of the present invention may contain one or more asymmetric centers (chiral centers or axial chirality) and are thus available as racemates, racemic mixtures, single enantiomers, diastereomeric compounds and single diastereomeric compounds in the form of enantiomers.
  • the number of asymmetric centers that can exist depends on the nature of the various substituents on the molecule. Each such asymmetric center will independently produce two optical isomers, and all possible optical isomers and diastereomeric mixtures, as well as pure or partially pure compounds, are included within the scope of the present invention.
  • the present invention is meant to include all such isomeric forms of these compounds.
  • composition a compound capable of inducing a desired pharmaceutical and/or physiological response through local and/or systemic action.
  • administering refers to the direct administration of the compound or composition, or the administration of a prodrug, derivative, or analog of the active compound Wait.
  • the present invention provides methods of treating diseases including, but not limited to, conditions involving EGFR mutations (eg, cancer) using the compounds of formula (1) or pharmaceutical compositions of the present invention.
  • methods for cancer treatment comprising administering to an individual in need thereof an effective amount of any of the foregoing pharmaceutical compositions comprising a compound of general structural formula (1).
  • the cancer is mediated by EGFR mutations.
  • the cancer is breast cancer, lung cancer, pancreatic cancer, colon cancer, bladder cancer, brain cancer, urothelial cancer, prostate cancer, liver cancer, ovarian cancer, head and neck cancer, stomach cancer, mesothelioma, or all cancers transfer.
  • the compounds of the present invention and their pharmaceutically acceptable salts can be prepared into various formulations, which contain the compounds of the present invention or their pharmaceutically acceptable salts and pharmacologically acceptable excipients or carriers within a safe and effective amount.
  • the "safe and effective amount” refers to: the amount of the compound is sufficient to significantly improve the condition without causing serious side effects.
  • the safe and effective dose of the compound is determined according to the age, disease condition, course of treatment and other specific conditions of the object to be treated.
  • “Pharmaceutically acceptable excipient or carrier” means: one or more compatible solid or liquid filler or gelling substances, which are suitable for human use and which must be of sufficient purity and sufficiently low toxicity .
  • “Compatibility” as used herein means that the components of the composition can be blended with the compounds of the present invention and with each other without significantly reducing the efficacy of the compounds.
  • pharmacologically acceptable excipients or carrier moieties are cellulose and its derivatives (such as sodium carboxymethyl cellulose, sodium ethyl cellulose, cellulose acetate, etc.), gelatin, talc, solid lubricants (such as stearic acid, magnesium stearate), calcium sulfate, vegetable oils (such as soybean oil, sesame oil, peanut oil, olive oil, etc.), polyols (such as propylene glycol, glycerol, mannitol, sorbitol, etc.), emulsifiers (such as Tween) ), wetting agents (such as sodium lauryl sulfate), colorants, flavors, stabilizers, antioxidants, preservatives, pyrogen-free water, etc.
  • cellulose and its derivatives such as sodium carboxymethyl cellulose, sodium ethyl cellulose, cellulose acetate, etc.
  • gelatin such as sodium carboxymethyl cellulose, sodium ethyl cellulose,
  • the compounds of the present invention may be administered orally, rectally, parenterally (intravenously, intramuscularly or subcutaneously), topically.
  • Solid dosage forms for oral administration include capsules, tablets, pills, powders and granules.
  • the active compound is mixed with at least one conventional inert excipient (or carrier), such as sodium citrate or dicalcium phosphate, or with (a) fillers or compatibilizers, for example, starch, lactose, sucrose, glucose, mannitol and silicic acid; (b) binders such as, for example, hydroxymethylcellulose, alginate, gelatin, polyvinylpyrrolidone, sucrose and acacia; (c) humectants, For example, glycerol; (d) disintegrants, such as agar, calcium carbonate, potato or tapioca starch, alginic acid, certain complex silicates, and sodium carbonate; (e) slow solvents, such as paraffin; (f) Absorption accelerators such as quaternary amine compounds; (g) wetting agents such as cetyl alcohol and glyceryl monostea
  • Solid dosage forms such as tablets, dragees, capsules, pills and granules can be prepared using coatings and shell materials, such as enteric coatings and other materials well known in the art. They may contain opacifying agents, and the release of the active compound or compounds in such compositions may be in a certain part of the digestive tract in a delayed manner. Examples of embedding components that can be employed are polymeric substances and waxes. If desired, the active compound may also be in microencapsulated form with one or more of the above-mentioned excipients.
  • Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups or tinctures.
  • liquid dosage forms may contain inert diluents conventionally employed in the art, such as water or other solvents, solubilizers and emulsifiers, for example, ethanol, isopropanol, ethyl carbonate, ethyl acetate, propylene glycol, 1 , 3-butanediol, dimethylformamide and oils, especially cottonseed oil, peanut oil, corn germ oil, olive oil, castor oil and sesame oil or mixtures of these substances.
  • inert diluents conventionally employed in the art, such as water or other solvents, solubilizers and emulsifiers, for example, ethanol, isopropanol, ethyl carbonate, ethyl acetate, propylene glycol, 1 , 3-butanediol, dimethylformamide and oils,
  • compositions can also contain adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring and perfuming agents.
  • adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring and perfuming agents.
  • Suspensions in addition to the active compounds, may contain suspending agents such as ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum methoxide and agar, or mixtures of these substances and the like.
  • suspending agents such as ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum methoxide and agar, or mixtures of these substances and the like.
  • compositions for parenteral injection may comprise physiologically acceptable sterile aqueous or anhydrous solutions, dispersions, suspensions or emulsions, and sterile powders for reconstitution into sterile injectable solutions or dispersions.
  • Suitable aqueous and non-aqueous carriers, diluents, solvents or excipients include water, ethanol, polyols and suitable mixtures thereof.
  • Dosage forms for topical administration of the compounds of this invention include ointments, powders, patches, sprays and inhalants.
  • the active ingredient is mixed under sterile conditions with a physiologically acceptable carrier and any preservatives, buffers, or propellants that may be required if necessary.
  • the compounds of the present invention may be administered alone or in combination with other pharmaceutically acceptable compounds.
  • a safe and effective amount of the compound of the present invention is suitable for mammals (such as human beings) in need of treatment, and the dose is the effective dose considered pharmaceutically, for a 60kg body weight, the daily dose is
  • the administration dose is usually 1 to 2000 mg, preferably 50 to 1000 mg.
  • the specific dosage should also take into account the route of administration, the patient's health and other factors, which are all within the skill of the skilled physician.
  • CDCl 3 stands for deuterated chloroform
  • EtOH stands for ethanol
  • MeOH stands for methanol
  • Hexane stands for n-hexane
  • DCM stands for dichloromethane
  • DIPEA diisopropylethylamine
  • Dioxane stands for 1,4 - dioxane
  • DMF for N,N-dimethylformamide
  • DMSO for dimethyl sulfoxide
  • THF for tetrahydrofuran
  • TEA triethylamine
  • EDCI for N-(3-dimethylaminopropyl)- N'-ethylcarbodiimide
  • HOBt for 1-hydroxybenzotriazole
  • K 3 PO 4 for potassium phosphate
  • NaHCO 3 for sodium bicarbonate
  • K 2 CO 3 for potassium carbonate
  • m-CPBA for m-chlorine Peroxybenzoic acid
  • Pd/C stands for palladium carbon
  • LiOH
  • Step 1 Synthesis of methyl 4'-methoxy-6-methyl-[2,3'-bipyridine]-4-carboxylate (compound int_2):
  • Step 2 Synthesis of 4'-methoxy-6-methyl-[2,3'-bipyridine]-4-carboxylic acid (compound int_3):
  • Methyl 4'-methoxy-6-methyl-[2,3'-bipyridine]-4-carboxylate (2.0 g, 7.7 mmol) was dissolved in a mixed solvent of methanol, tetrahydrofuran and water (1:1 : 1, 15 mL), lithium hydroxide hydrate (1.96 g, 46.5 mmol) was added, and the reaction was stirred at room temperature for 3 h.
  • LC-MS monitored the completion of the reaction, and the pH was adjusted to about 5-6 with concentrated hydrochloric acid under an ice bath, and a solid was precipitated and filtered. , and the filter cake was dried to obtain 1.0 g of a light yellow solid with a yield of 53%.
  • Step 3 Synthesis of 1-((5-fluoro-2-nitrophenyl)amino)-2-methylpropan-2-ol (compound int_5):
  • Step 4 1-Methyl-1-((5-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)-2-nitrophenyl)amino)propane-2- Synthesis of alcohol (compound int_6):
  • Step 5 1-((2-Amino-5-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)amino)-2-methylpropan-2-ol Synthesis of (compound int_7):
  • Step 6 1-(2-Amino-6-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)-1H-benzo[d]imidazol-1-yl)-2 - Synthesis of methylpropan-2-ol (compound int_8):
  • Step 7 N-(1-(2-Hydroxy-2-methylpropyl)-6-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)-1H-benzo Synthesis of [d]imidazol-2-yl)-4'-methoxy-6-methyl-[2,3'-bipyridine]-4-carboxamide (compound 1):
  • Step 1 Synthesis of 2-bromo-5-fluoroisonicotinic acid methyl ester (compound int_2):
  • Step 2 Synthesis of methyl 5-fluoro-2-methylisonicotinate (compound int_3):
  • Step 4 Synthesis of methyl 2-chloro-3-fluoro-6-methylisonicotinate (compound int_5):
  • Step 5 Synthesis of methyl 3-fluoro-4'-methoxy-6-methyl-[2,3'-bipyridine]-4-carboxylate (compound int_6):
  • Step 6 Synthesis of 3-fluoro-4'-methoxy-6-methyl-[2,3'-bipyridine]-4-carboxylic acid (compound int_7):
  • Methyl 3-fluoro-4'-methoxy-6-methyl-[2,3'-bipyridine]-4-carboxylate (3.00 g, 10.86 mmol) was dissolved in a mixture of methanol, tetrahydrofuran and water Lithium hydroxide hydrate (2.73 g, 65.16 mmol) was added to the solvent (1:1:1, 15 mL), and the reaction was stirred at room temperature for 2 h. The completion of the reaction was monitored by LC-MS, water (30 mL) was added, and DCM (200 mL) was added to the aqueous phase.
  • Step 7 Synthesis of 1-((4-fluoro-2-nitrophenyl)amino)-2-methylpropyl-2-ol (compound int-9):
  • Step 8 2-Methyl 1-1-((4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)-2-nitrophenyl)amino)propyl- Synthesis of 2-ol (compound int_10):
  • Step 9 1-((2-Amino-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)amino)-2-methylpropyl-2- Synthesis of alcohol (compound int_11):
  • Step 10 1-(2-Amino-5-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)-1H-benzo[d]imidazol-1-yl)-2 - Synthesis of methylpropyl-2-ol (compound int_12):
  • Step 11 3-Fluoro-N-(1-(2-hydroxy-2-methylpropyl)-5-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)- Synthesis of 1H-benzo[d]imidazol-2-yl)-4'-methoxy-6-methyl-[2,3'-bipyridine]-4-carboxamide (compound 2):
  • the target compound 3-332 in Table 1 can be obtained.
  • Example 2 Detection of the inhibitory activity of the compounds of the present invention on EGFR (del19/T790M/C797S), EGFR (L858R/T790M/C797S) or EGFR (WT) enzymes
  • WT or mutant EGFR protein was incubated with serially diluted compounds at 28°C for 10 minutes, biotin-labeled universal tyrosine kinase substrate (TK) and ATP were added, and the reaction was performed at room temperature for 40 minutes. After the reaction was terminated, Eu3+-Cryptate-labeled antibody against TK and streptavidin-XL665 were added and incubated at room temperature for 60 minutes. The level of TK substrate phosphorylation was quantified by detecting luminescence at 615 nm and 665 nm and calculating the 665/615 ratio. Compared to the control group, the compound inhibition percentage and IC50 were calculated. The results are shown in Table 2 below.
  • +++ means inhibition rate greater than 50%.
  • the compounds of the present invention have good inhibitory activity on the enzymatic activities of EGFR (del19/T790M/C797S) and EGFR (L858R/T790M/C797S), and have good selectivity for EGFR (WT).

Abstract

本发明涉及一种通式(1)所示的化合物及其制备方法，及通式(1)化合物及其各异构体、各晶型、药学上可接受的盐、水合物或溶剂合物作为EGFR抑制剂在抗肿瘤等EGFR相关疾病的药物制备中的用途。

Description

新型苯并咪唑化合物
本申请要求申请日为2020年7月1日的中国申请CN202010629495.X的优先权。本申请引用上述中国申请的全文。
技术领域
本发明属涉及药物化学领域，更具体而言，涉及一类苯并咪唑化合物，及其制备方法和该类化合物作为EGFR抑制剂在制备抗肿瘤药物中的用途。
背景技术
肺癌是常见的恶性肿瘤之一，每年全球新发肺癌病例数约在160万，因肺癌导致的死亡患者每年约在140万。而其中，非小细胞肺癌(non-small cell lung cancer，NSCLC)约占肺癌总数的80％-85％左右(Nature，2018，553，446-454)。
EGFR蛋白家族是一类蛋白激酶，负责传导促有丝分裂信号，在生长发育中发挥了重要的作用。大量的体外肿瘤细胞，动物模型以及人类肿瘤样本的分析和研究表明EGFR家族蛋白的突变导致人类肿瘤发展，是多种癌症发生和发展的重要诱因之一。因此靶向和抑制EGFR突变蛋白的活性是治疗相关肿瘤的重要手段。
研究显示，EGFR基因突变在大约12到47％的非小细胞肺癌中能够被发现。在非小细胞肺癌中，两类最常见的EGFR基因突变为外显子19缺失(del19)和在外显子21中的L858R错译(L858 missense mutation)突变。这两类突变会导致EGFR蛋白不依赖配体而持续激活。虽然具有EGFR蛋白Del19或L858R突变的NSCLC患者对于EGFR蛋白激酶抑制剂(EGFRTKI)例如erlotinib、gefitinib、afatinib或osimertinib的靶向治疗更为敏感，能够在临床上获得较高的(60-85％左右)的客观缓解率(objective response rate，ORR)，但是这一响应通常不会持续太久，大多数使用第一代或第二代EGFR TKIs的患者会在约11个月时发生疾病进展。耐药分析显示在大约50-70％耐药患者中，耐药分子机制是EGFR基因获得第二种突变，称为T790M突变(T790M+)(CancerDiscov.2012，2，872-5)。这一二次突变使第一代和第二代EGFR TKIs对于突变肿瘤细胞失去抑制活性。
Osimertinib作为第三代共价EGFR TKI，被开发用来治疗具有EGFR del19和L858R突变并伴随或不伴随T790M突变的肿瘤。虽然osimertinib针对T790M突变导致的耐药具有较高的响应率，然而，大约70％的患者最终也会发生耐药，疾病会在大约10个月后 再次进展(Lung Cancer.2017，108，228-231)。对第三代EGFR TKI耐药的分子机制研究显示，在大约20-40％经历osimertinib治疗并复发的病人中，一个主要的耐药机制是EGFR基因获得第三重突变，即C797S突变。而且，在经过第三代EGFRTKI治疗后，具有EGFR del19/L858R T790M C797S突变体的患者已不能再对第一代、第二代或第三代EGFRTKIs响应。2015年Thress等人首次报道了基于15例患者对于osimertinib的耐药分析，发现其中约有40％的耐药由C797S突变而来(Nature Medicine，2015，21，560-562)。2017年ASCO，Piotrowska和周彩存各报道了23例和99例患者耐药分析，两者的分析结果都显示大约有22％左右的耐药由C797S突变引起。所以靶向抑制EGFR del19/L858R T790M C797S突变能够克服osimertinib耐药，但目前还未有上市的EGFR TKI能够抑制EGFR del19/L858R T790M C797S突变体，所以研究和发现第四代EGFR TKI来满足这一尚未被满足的临床需求非常迫切。
EGFR del19/L858R T790M C797S突变体作为经第三代EGFR TKI治疗后新浮现的EGFR突变体，目前的研究还不是很多。目前只有少数第四代EGFRTKI被报道能够抑制EGFR del19/L858R T790M C797S突变体。比如Boehringer Ingelheim报道了一类大环化合物BI-4020具有抗EGFR del19/L858R T790M C797S突变体活性以及体内抗肿瘤活性(J Med Chem.2019，62，10272-10293)。而专利WO2019/015655中，报道了一类芳基磷氧化合物具有抗EGFR del19/L858R T790M C797S突变体活性以及体内抗肿瘤活性。其通式A及代表化合物B(专利中实施例41)结构如下(式中各符号的定义请参照该专利)：
Figure PCTCN2021103366-appb-000001
目前，研究和发现具有针对EGFR del19/L858R T790M C797S突变活性好、安全的化合物存在迫切的需求。
发明内容
本发明旨在提供一种通式(1)所示的化合物或其各异构体、各晶型、药学上可接受的 盐、水合物或溶剂合物：
Figure PCTCN2021103366-appb-000002
通式(1)中：
R 1为(C3-C6)烷基、(C3-C6)环烷基或(4-7元)杂环烷基，其中所述(C3-C6)烷基、(C3-C6)环烷基、(4-7元)杂环烷基各自独立任选被1个或多个下列基团取代：-H、-OH、卤素、(C1-C6)烷基和(C1-C6)烷氧基；
R 2为-H或者卤素；
R 3为-H、卤素、-CN、-NH 2、-NR 3aR 3b、(C1-C4)烷基、(C1-C4)卤代烷基、(C2-C4)烯基或(C2-C4)炔基；
R 4为苯基、(5-6元)杂芳基或9元杂芳基，其中所述苯基、(5-6元)杂芳基或9元杂芳基各自独立任选被1个或多个下列基团取代：-H、卤素、-OH、-CN、(C1-C6)烷基、(C3-C6)环烷基、(C1-C6)卤代烷基、-O-(C1-C6)烷基、-O-(C3-C6)环烷基、-O-(C1-C6)卤代烷基、-NR 4aR 4b、-C(O)NHR 4aR 4b和-(CH 2) mNR 4aR 4b；
当R 2为-H时，R 5为-(CH 2) n-(3-11元)杂环烷基、-O-(CH 2) m-(4-9元)杂环烷基、-O-(CH 2) m-NR 5aR 5b、(C1-C6)烷氧基或(C1-C6)卤代烷氧基，其中所述(3-11元)杂环烷基各自独立被1个或多个下列基团取代：-R 5c、-(CH 2) m-NR 5aR 5b、-N(R 4a)-(CH 2) m-NR 5aR 5b、-O-(CH 2) m-NR 5aR 5b和-O-(CH 2) m-OR 5a，和其中所述(4-9元)杂环烷基、(C1-C6)烷氧基或(C1-C6)卤代烷氧基各自独立任选被1个或多个下列基团取代：-H、-CN、-OH、(C1-C6)烷基、-(C1-C6)环烷基、-NR 5aR 5b和卤素；
当R 2为卤素时，R 5为-H、卤素、-(CH 2) n-(3-11元)杂环烷基、-O-(CH 2) m-(4-9元)杂环烷基、-O-(CH 2) m-NR 5aR 5b、(C1-C6)烷氧基、(C1-C6)卤代烷氧基、-NR 5aR 5b、-N(R 4a)-(CH 2) m-NR 5aR 5b或(C1-C6)烷基，其中所述(3-11元)杂环烷基各自独立任选被1个或多个下列基团取代：(C1-C4)烷基、(C1-C4)烷氧基、(C3-C6)环烷基、-NR 5aR 5b、-(CH 2) m-NR 5aR 5b、-(CH 2) m-OR 5a、-N(R 4a)-(CH 2) m-NR 5aR 5b、-O-(CH 2) m-NR 5aR 5b和-O-(CH 2) m-OR 5a和-R 5c，和其中所述(4-9元)杂环烷基、(C1-C6)烷氧基、(C1-C6)烷基或(C1-C6)卤代烷氧基各自独立任选被1个或多个下列基团取代：-H、-CN、-OH、(C1-C6)烷基、-(C1-C6)环烷基、-NR 5aR 5b和卤 素；
R 6为-H、卤素、-(CH 2) n-(3-11元)杂环烷基、-O-(CH 2) m-(4-9元)杂环烷基、-O-(CH 2) m-NR 5aR 5b、(C1-C6)烷氧基、(C1-C6)卤代烷氧基、-NR 5aR 5b、-N(R 4a)-(CH 2) m-NR 5aR 5b或(C1-C6)烷基，其中所述(3-11元)杂环烷基各自独立任选被1个或多个下列基团取代：(C1-C4)烷基、(C1-C4)烷氧基、(C3-C6)环烷基、-NR 5aR 5b、-(CH 2) m-NR 5aR 5b、-(CH 2) m-OR 5a、-N(R 4a)-(CH 2) m-NR 5aR 5b、-O-(CH 2) m-NR 5aR 5b和-O-(CH 2) m-OR 5a和-R 5c，和其中所述(4-9元)杂环烷基、(C1-C6)烷氧基、(C1-C6)卤代烷氧基或(C1-C6)烷基各自独立任选被1个或多个下列基团取代：-H、-CN、-OH、(C1-C6)烷基、-(C1-C6)环烷基、-NR 5aR 5b和卤素；
R 7为-H或者卤素；
R 3a和R 3b各自独立地为-H或(C1-C4)烷基；
R 4a和R 4b各自独立地为-H或(C1-C6)烷基；
R 5a和R 5b各自独立地为-H、(C1-C6)烷基或(C3-C6)环烷基，或R 5a和R 5b与其连接的N原子能够共同组成一个(3-11元)杂环烷基，此杂环烷基各自独立任选被1个或多个下列基团取代：-H、-(C1-C6)烷基和卤素；
R 5c为(3-11元)杂环烷基，此杂环烷基各自独立任选被1个或多个下列基团取代：-H、-(C1-C6)烷基、-(C1-C6)环烷基、卤素和-CD 3；
m为1或2的整数；和
n为0、1或2的整数。
在另一优选例中，其中所述通式(1)中，R 1为(C3-C6)烷基、(C3-C6)环烷基或(4-7元)杂环烷基，其中所述(C3-C6)烷基、(C3-C6)环烷基、(4-7元)杂环烷基各自独立任选被1个或多个下列基团取代：-H、-OH、-F、-CH 3和-OCH 3。
在另一优选例中，其中所述通式(1)中，R 1为：
Figure PCTCN2021103366-appb-000003
在另一优选例中，其中所述通式(1)中，R 2为-H或者-F。
在另一优选例中，其中所述通式(1)中，R 3为-H、-F、-CN、-NH 2、-N(CH 3) 2、-CH 3、-CH 2CH 3、-CF 3、-CHF 2或-C≡CH。
在另一优选例中，其中所述通式(1)中，R 4为苯基、(5-6元)杂芳基或9元杂芳基，其中所述苯基、(5-6元)杂芳基或9元杂芳基各自独立任选被1个或多个下列基团取代：-H、-F、-Cl、-OH、-CN、-CH 3、-OCH 3、-N(CH 3) 2、和-NH 2。
在另一优选例中，其中所述通式(1)中，R 4为：
Figure PCTCN2021103366-appb-000004
在另一优选例中，其中所述通式(1)中，R 2为-H，和R 5为(4-10元)杂环烷基、-(CH 2)-(4-10元)杂环烷基、-O-(CH 2)-(4-9元)杂环烷基、-O-(CH 2) 2-(4-9元)杂环烷基、-O-(CH 2) 2-N(CH 3) 2、-O-(CH 2) 2-N(CH 2CH 3) 2或-OCH 3，其中所述(4-10元)杂环烷基为：
Figure PCTCN2021103366-appb-000005
Figure PCTCN2021103366-appb-000006
所述此(4-10元)杂环烷基各自独立被1个或多个下列基团取代：
Figure PCTCN2021103366-appb-000007
Figure PCTCN2021103366-appb-000008
Figure PCTCN2021103366-appb-000009
和其中所述(4-9元)杂环烷基为：
Figure PCTCN2021103366-appb-000010
Figure PCTCN2021103366-appb-000011
所述此(4-9元)杂环烷基各自独立被1个或多个下列基团取代：-H、-F、-CH 3、-CN、
Figure PCTCN2021103366-appb-000012
-OH、-OCH 3和-N(CH 3) 2。
在另一优选例中，其中所述通式(1)中，R 2为-H，和R 5为：-OCH 3、-O-(CH 2) 2-N(CH 3) 2、-O-(CH 2) 2-N(CH 2CH 3) 2、
Figure PCTCN2021103366-appb-000013
Figure PCTCN2021103366-appb-000014
Figure PCTCN2021103366-appb-000015
Figure PCTCN2021103366-appb-000016
在另一优选例中，其中所述通式(1)中，R 2为-F，和R 5为-H、-F、-Cl、(4-10元)杂环烷基、-(CH 2)-(4-10元)杂环烷基、-O-(CH 2)-(4-9元)杂环烷基、-O-(CH 2) 2-(4-9元)杂环烷基、-O-(CH 2) 2-N(CH 3) 2、-O-(CH 2) 2-N(CH 2CH 3) 2、-OCH 3、-N(CH 2CH 3) 2、-NH-(CH 2) 2-N(CH 3) 2、-N(CH 3)-(CH 2) 2-N(CH 3) 2或(C1-C6)烷基，其中所述(4-10元)杂环烷基为：
Figure PCTCN2021103366-appb-000017
Figure PCTCN2021103366-appb-000018
所述此(4-10元)杂环烷基各自独立任选被1个或多个下列基团取代：-H、-F、-CH 3、-CN、
Figure PCTCN2021103366-appb-000019
-OH、-OCH 3、-N(CH 3) 2、
Figure PCTCN2021103366-appb-000020
Figure PCTCN2021103366-appb-000021
Figure PCTCN2021103366-appb-000022
Figure PCTCN2021103366-appb-000023
和其中所述(4-9元)杂环烷基为：
Figure PCTCN2021103366-appb-000024
Figure PCTCN2021103366-appb-000025
Figure PCTCN2021103366-appb-000026
所述此(4-9元)杂环烷基各自独立任选被1个或多个下列基团取代：-H、-F、-CH 3、-CN、
Figure PCTCN2021103366-appb-000027
-OH、-OCH 3和-N(CH 3) 2。
在另一优选例中，其中所述通式(1)中，R 2为-F，和R 5为：-H、-F、-Cl、-OCH 3、-N(CH 3) 2、-O-(CH 2) 2-N(CH 3) 2、-O-(CH 2) 2-N(CH 2CH 3) 2、-N(CH 2CH 3) 2、-NH-(CH 2) 2-N(CH 3) 2、-N(CH 3)-(CH 2) 2-N(CH 3) 2、
Figure PCTCN2021103366-appb-000028
Figure PCTCN2021103366-appb-000029
Figure PCTCN2021103366-appb-000030
Figure PCTCN2021103366-appb-000031
在另一优选例中，其中所述通式(1)中，R 6为-H、-F、-Cl、(4-10元)杂环烷基、-(CH 2)-(4-10元)杂环烷基、-O-(CH 2)-(4-9元)杂环烷基、-O-(CH 2) 2-(4-9元)杂环烷基、-O-(CH 2) 2-N(CH 3) 2、-O-(CH 2) 2-N(CH 2CH 3) 2、-OCH 3、-N(CH 2CH 3) 2、-NH-(CH 2) 2-N(CH 3) 2、-N(CH 3)-(CH 2) 2-N(CH 3) 2或(C1-C6)烷基，其中所述(4-10元)杂环烷基为：
Figure PCTCN2021103366-appb-000032
Figure PCTCN2021103366-appb-000033
所述此(4-10元)杂环烷基各自独立任选被1个或多个下列基团取代：-H、-F、-CH 3、-CN、
Figure PCTCN2021103366-appb-000034
-OH、-OCH 3、-N(CH 3) 2、
Figure PCTCN2021103366-appb-000035
Figure PCTCN2021103366-appb-000036
Figure PCTCN2021103366-appb-000037
Figure PCTCN2021103366-appb-000038
和其中所述(4-9元)杂环烷基为：
Figure PCTCN2021103366-appb-000039
Figure PCTCN2021103366-appb-000040
所述此(4-9元)杂环烷基各自独立任选被1个或多个下列基团取代：-H、-F、-CH 3、-CN、
Figure PCTCN2021103366-appb-000041
-OH、-OCH 3和-N(CH 3) 2。
在另一优选例中，其中所述通式(1)中，R 6为：-H、-F、-Cl、-OCH 3、-N(CH 3) 2、-O-(CH 2) 2-N(CH 3) 2、-O-(CH 2) 2-N(CH 2CH 3) 2、-N(CH 2CH 3) 2、-NH-(CH 2) 2-N(CH 3) 2、-N(CH 3)-(CH 2) 2-N(CH 3) 2、
Figure PCTCN2021103366-appb-000042
Figure PCTCN2021103366-appb-000043
Figure PCTCN2021103366-appb-000044
Figure PCTCN2021103366-appb-000045
在另一优选例中，其中所述通式(1)中，R 7为-H、-F或-Cl。
在各种不同实施方式中，本发明代表性化合物具有以下结构之一：
Figure PCTCN2021103366-appb-000046
Figure PCTCN2021103366-appb-000047
Figure PCTCN2021103366-appb-000048
Figure PCTCN2021103366-appb-000049
Figure PCTCN2021103366-appb-000050
Figure PCTCN2021103366-appb-000051
Figure PCTCN2021103366-appb-000052
Figure PCTCN2021103366-appb-000053
Figure PCTCN2021103366-appb-000054
Figure PCTCN2021103366-appb-000055
Figure PCTCN2021103366-appb-000056
Figure PCTCN2021103366-appb-000057
Figure PCTCN2021103366-appb-000058
Figure PCTCN2021103366-appb-000059
Figure PCTCN2021103366-appb-000060
Figure PCTCN2021103366-appb-000061
Figure PCTCN2021103366-appb-000062
本发明的另一个目的是提供了一种药物组合物，其含有药学上可接受的载体、稀释剂和/或赋形剂，以及本发明通式(1)化合物、或其各异构体、各晶型、药学上可接受的盐、水合物或溶剂合物作为活性成分。
本发明的再一个目的提供了本发明的通式(1)所示的化合物、或其各异构体、各晶型、药学上可接受的盐、水合物或溶剂合物或上述药物组合物用于制备治疗、调节或预防与EGFR突变相关疾病的药物中的应用。所述与EGFR突变相关疾病可为癌症；其中所述癌症例如是血液癌或实体瘤，优选为非小细胞肺癌、头颈癌、乳腺癌、肾癌、胰腺癌、子宫颈癌、食道癌、胰腺癌、前列腺癌、膀胱癌、结肠直肠癌、卵巢癌、胃癌、脑恶性肿瘤包括成胶质细胞瘤等，或它们的任何组合。
本发明的再一个目的还提供治疗、调节或预防与EGFR突变相关疾病的方法，包括对受试者给与治疗有效量的本发明的通式(1)所示的化合物、或其各异构体、各晶型、药学上可接受的盐、水合物或溶剂合物或上述药物组合物。
通过合成和仔细研究了多类涉及具有EGFR抑制作用的新化合物，发明人发现在通式(1)化合物中，当R 2、R 5或R 6为如上文所定义基团时，化合物意外地具有很强的EGFR del19/T790M/C797S和EGFR L858R/T790M/C797S抑制活性，并且对于野生型EGFR WT有较高的选择性。
应理解，本发明的前述一般性描述和以下详细描述都是示例性和说明性的，旨在提供对所要求保护的本发明的进一步说明。
化合物的合成
下面具体地描述本发明通式(1)化合物的制备方法，但这些具体方法不对本发明构成任何限制。
以上说明的通式(1)化合物可使用标准的合成技术或公知的技术与文中结合的方法来合成。此外，在此提到的溶剂，温度和其他反应条件可以改变。用于化合物的合成的起始物料可以由合成或从商业来源上获得。本文所述的化合物和其他具有不同取代基的有关化合物可使用公知的技术和原料来合成，包括发现于March，ADVANCED ORGANIC CHEMISTRY 4 thEd.，(Wiley 1992)；Carey和Sundberg，ADVANCED ORGANIC CHEMISTRY 4 th Ed.，Vols.A和B(Plenum 2000，2001)，Green和Wuts，PROTECTIVE GROUPS IN ORGANIC SYNTHESIS 3 rdEd.，(Wiley 1999)中的方法。化合物制备的一般方法可通过使用适当的试剂和在此提供的分子式中引入不同基团的条件来改变。
一方面，本文所述的化合物根据工艺中公知的方法。然而方法的条件，例如反应物、溶剂、碱、所用化合物的量、反应温度、反应所需时间等不限于下面的解释。本发明化合物还可以任选将在本说明书中描述的或本领域已知的各种合成方法组合起来而方便的制得，这样的组合可由本发明所属领域的技术人员容易的进行。一方面，本发明还提供了一种所述的通式(1)所示化合物的制备方法，其中通式(1)化合物可采用下列一般反应流程1或一般反应流程2制备：
一般反应流程1
Figure PCTCN2021103366-appb-000063
通式(1)化合物的实施方式可根据一般反应流程1制备，其中R 1、R 3、R 4、R 5、R 6和R 7如上文中所定义，X表示溴或氯，B表示硼酸、硼酸酯或三氟硼酸盐。如一般反应流程1所示，化合物1-1和R 4-B发生偶联反应生成化合物1-2，化合物1-2通过水解反应生成中间体1-3，化合物1-4通过还原反应生成化合物1-5，化合物1-5进行关环反应生成中间体1-6，中间体1-6与中间体1-3偶联缩合得到目标化合物1-7。
一般反应流程2
Figure PCTCN2021103366-appb-000064
通式(1)化合物还可根据一般反应流程2制备，其中R 1、R 3、R 4、R 5、R 6和R 7如上文中所定义，X表示溴或氯，B表示硼酸、硼酸酯或三氟硼酸盐。如一般反应流程1所示，化合物2-1和R 4-B发生偶联反应生成化合物2-2，化合物2-2通过水解反应生成中间体2-3，化合物2-4通过还原反应生成化合物2-5，化合物2-5进行关环反应生成中间体2-6，中间体2-6与中间体2-3偶联缩合得到目标化合物2-7。
化合物的进一步形式
“药学上可接受”这里指一种物质，如载体或稀释液，不会使化合物的生物活性或性质消失，且相对无毒，如，给予个体某物质，不会引起不想要的生物影响或以有害的方式与任何其含有的组分相互作用。
术语“药学上可接受的盐”指一种化合物的存在形式，该形式不会引起对给药有机体的重要的刺激，且不会使化合物的生物活性和性质消失。在某些具体方面，药学上可接 受的盐是通过通式(1)化合物与酸反应获得，如盐酸、氢溴酸、氢氟酸、硫酸、磷酸、硝酸、磷酸等无机酸，甲酸、乙酸、丙酸、草酸、三氟乙酸、丙二酸、琥珀酸、富马酸、马来酸、乳酸、苹果酸、酒石酸、柠檬酸、苦味酸、甲磺酸、苯磺酸、对甲苯磺酸等有机酸以及天冬氨酸、谷氨酸等酸性氨基酸。
应理解药学上可接受的盐的参考包括溶剂添加形式或结晶形式，尤其是溶剂化物或多晶型。溶剂化物含有化学计量或非化学计量的溶剂，且是在与药学上可接受溶剂如水，乙醇等，结晶化过程中选择性形成的。当溶剂是水时形成水合物，或当溶剂是乙醇时形成醇化物。通式(1)化合物的溶剂化物按照本文所述的方法，很方便的制得或形成。举例说明，通式(1)化合物的水合物从水/有机溶剂的混合溶剂中重结晶而方便的制得，使用的有机溶剂包括但不限于，四氢呋喃、丙酮、乙醇或甲醇。此外，在此提到的化合物能够以非溶剂化和溶剂化形式存在。总之，对于在此提供的化合物和方法为目的，溶剂化形式被认为相当于非溶剂化形式。
在其他具体实施例中，通式(1)化合物被制备成不同的形式，包括但不限于，无定形，粉碎形和毫微-粒度形式。此外，通式(1)化合物包括结晶型，也可以作为多晶型。多晶型包括化合物的相同元素组成的不同晶格排列。多晶型通常有不同的X-射线衍射图、红外光谱、熔点、密度、硬度、晶型、光和电的性质、稳定性和溶解性。不同的因素如重结晶溶剂，结晶速率和贮存温度可能引起单一晶型为主导。
在另一个方面，通式(1)化合物可能存在手性中心和/或轴手性，并因此以消旋体、外消旋混合物、单一对映体、非对映异构体化合物和单一非对映体的形式、和顺反异构体的形式出现。每个手性中心或轴手性将独立地产生两个旋光异构体，并且所有可能的旋光异构体和非对映体混合物以及纯或部分纯的化合物包括在本发明的范围之内。本发明意味着包括这些化合物的所有这种异构形式。
本发明的化合物可以在一个或多个构成该化合物的原子上包含非天然比例的原子同位素。例如，可用放射性同位素标记化合物，比如氚( 3H)、碘-125( 125I)和C-14( 14C)。又例如，可用重氢取代氢原子形成氘代化合物，氘与碳构成的键比普通氢和碳构成的键更坚固，相比于未氘代药物，通常氘代药物具有降低毒副作用、增加药物稳定性、增强疗效、延长药物体内半衰期等优势。本发明的化合物的所有同位素组成的变换，无论放射性与否，都包含在本发明的范围之内。
术语
如果无另外说明，用于本发明申请，包括说明书和权利要求书中的术语，定义如下。 必须注意，在说明书和所附的权利要求书中，如果文中无另外清楚指示，单数形式“一个”包括复数意义。如果无另外说明，使用质谱、核磁、HPLC、蛋白化学、生物化学、重组DNA技术和药理的常规方法。在本申请中，如果无另外说明，使用“或”或“和”指“和/或”。
除非另有规定，“烷基”指饱和的脂肪烃基团，包括1至6个碳原子的直链和支链基团。优选含有1至4个碳原子的低级烷基，例如甲基、乙基、丙基、2-丙基、正丁基、异丁基、叔丁基。如本文所用，“烷基”包括未取代和取代的烷基，尤其是被一个或多个卤素所取代的烷基。优选的烷基选自CH 3、CH 3CH 2、CF 3、CHF 2、CF 3CH 2、CF 3(CH 3)CH、 iPr、 nPr、 iBu、 nBu或 tBu。
除非另有规定，“烯基”指含有碳-碳双键的不饱和脂肪烃基团，包括1至14个碳原子的直链或支链基团。优选含有1至4个碳原子的低级烯基，例如乙烯基、1-丙烯基、1-丁烯基或2-甲基丙烯基。
除非另有规定，“炔基”指含有碳-碳叁键的不饱和脂肪烃基团，包括1至14个碳原子的直链和支链基团。优选含有1至4个碳原子的低级炔基，例如乙炔基、1-丙炔基或1-丁炔基。
除非另有规定，“环烷基”指3至14元全碳单环脂肪烃基团，其中一个或多个环可以含有一个或多个双键，但没有一个环具有完全共轭的π电子系统。例如，环丙基、环丁基、环戊基、环己烷、环己二烯等。
除非另有规定，“烷氧基”指通过醚氧原子键合到分子其余部分的烷基。代表性的烷氧基为具有1-6个碳原子的烷氧基，如甲氧基、乙氧基、丙氧基、异丙氧基、丁氧基、异丁氧基、仲丁氧基和叔丁氧基。如本文所用，“烷氧基”包括未取代和取代的烷氧基，尤其是被一个或多个卤素所取代的烷氧基。优选的烷氧基选自OCH 3、OCF 3、CHF 2O、CF 3CH 2O、 i-PrO、 n-PrO、 i-BuO、 n-BuO或 t-BuO。
除非另有规定，“芳基”指碳氢芳香基团，芳基是单环或多环的，例如单环芳基环与一个或多个碳环芳香基团稠和。芳基的例子包括但不限于，苯基、萘基和菲基。
除非另有规定，“亚芳基”指二价的如上所定义的芳基。亚芳基的例子包括但不限于，亚苯基、亚萘基和亚菲基。
除非另有规定，“杂芳基”指含有一个或多个杂原子(O、S或N)的芳香基团，杂芳基是单环或多环的。例如单环杂芳基环与一个或多个碳环芳香基团或其它单环杂环烷基基团稠和。杂芳基的例子包括但不限于，吡啶基、哒嗪基、咪唑基、嘧啶基、吡唑基、三唑基、吡嗪基、喹啉基、异喹啉基、呋喃基、噻吩基、异噁唑基、噻唑基、噁唑基、异噻唑 基、吡咯基、吲哚基、苯并咪唑基、苯并呋喃基、苯并噻唑基、苯并噻吩基、苯并噁唑基、苯并吡啶基、吡咯并嘧啶基、1H-吡咯[3，2-b]吡啶基、1H-吡咯[2，3-c]吡啶基、1H-吡咯[3，2-c]吡啶基、1H-吡咯[2，3-b]吡啶基、
Figure PCTCN2021103366-appb-000065
除非另有规定，“杂环烷基”指非芳香族环或环系统，其可以任选地含有一个或多个亚烯基作为环结构的一部分，其具有至少一个独立地选自硼、磷、氮、硫、氧和磷的杂原子环成员。杂环烷基可以包括单环、双环、螺环或多环(例如具有两个稠合或桥接环)环系统。在一些实施例中，杂环烷基为具有1、2或3个独立地选自氮、硫和氧的杂原子的单环基团。杂环烷基的成环碳原子和杂原子可以任选地氧化以形成氧代或硫离子基或其他氧化键(例如C(O)、S(O)、C(S)或S(O)2、N-氧化物等)，或氮原子可以季铵化。杂环烷基可以经由成环碳原子或成环杂原子而连接。在一些实施例中，杂环烷基含有0至3个双键。在一些实施例中，杂环烷基含有0至2个双键。杂环烷基的定义中还包括具有一个或多个与杂环烷基环稠合(即，与其共用键)的芳香族环的部分，例如哌啶、吗啉、氮杂环庚三烯等的苯并或噻吩基衍生物。含有稠合芳香族环的杂环烷基可以经由任何成环原子，包括稠合芳香族环的成环原子而连接。杂环烷基的实例包括氮杂环丁基、氮杂环庚基、二氢苯并呋喃基、二氢呋喃基、二氢吡喃基、N-吗啉基、3-氧杂-9-氮杂螺[5.5]十一烷基、1-氧杂-8-氮杂螺[4.5]癸烷基、哌啶基、哌嗪基、氧代哌嗪基、吡喃基、吡咯烷基、奎宁基、四氢呋喃基、四氢吡喃基、1，2，3，4-四氢喹啉基、莨菪烷基、4，5，6，7-四氢噻唑并[5，4-c]吡啶基、4，5，6，7-四氢-1H-咪唑并[4，5-c]吡啶、N-甲基哌啶基、四氢咪唑基、吡唑烷基、丁内酰胺基、戊内酰胺基、咪唑啉酮基、乙内酰脲基、二氧戊环基、邻苯二甲酰亚胺基、嘧啶-2，4(1H，3H)-二酮基、1，4-二氧六环基、吗啉基、硫代吗啉基、硫代吗啉-S-氧化物基、硫代吗啉-S，S-氧化物基、哌嗪基、吡喃基、吡啶酮基、3-吡咯啉基、噻喃基、吡喃酮基、四氢噻吩基、2-氮杂螺[3.3]庚烷基、吲哚啉基、
Figure PCTCN2021103366-appb-000066
Figure PCTCN2021103366-appb-000067
除非另有规定，“卤素”(或卤代基)是指氟、氯、溴或碘。在基团名前面出现的术语“卤代”(或“卤素取代”)表示该基团是部分或全部卤代，也就是说，以任意组合的方式被F， Cl，Br或I取代，优选被F或Cl取代。
“任选”或“任选地”指的是随后描述的事件或状况可能但不是必需出现，并且该描述包括其中所述事件或状况发生的情况以及所述事件或状况不发生的情况。
取代基“-O-CH 2-O-”指该取代基中二个氧原子和杂环烷基、芳基或杂芳基二个相邻的碳原子连接，比如：
Figure PCTCN2021103366-appb-000068
当一个连接基团的数量为0时，比如-(CH 2) 0-，表示该连接基团为单键。
当其中一个变量选自化学键时，表示其连接的两个基团直接相连，比如X-L-Y中L代表化学键时表示该结构实际上是X-Y。
除非另有说明，用楔形实线键
Figure PCTCN2021103366-appb-000069
和楔形虚线键
Figure PCTCN2021103366-appb-000070
表示一个立体中心的绝对构型，用直形实线键
Figure PCTCN2021103366-appb-000071
和直形虚线键
Figure PCTCN2021103366-appb-000072
表示立体中心的相对构型，用波浪线
Figure PCTCN2021103366-appb-000073
表示楔形实线键
Figure PCTCN2021103366-appb-000074
或楔形虚线键
Figure PCTCN2021103366-appb-000075
或用波浪线
Figure PCTCN2021103366-appb-000076
表示直形实线键
Figure PCTCN2021103366-appb-000077
或直形虚线键
Figure PCTCN2021103366-appb-000078
特定药学及医学术语
术语“可接受的”，如本文所用，指一个处方组分或活性成分对一般治疗目标的健康没有过分的有害影响。
术语“治疗”、“治疗过程”或“疗法”如本文所用，包括缓和、抑制或改善疾病的症状或状况；抑制并发症的产生；改善或预防潜在代谢综合症；抑制疾病或症状的产生，如控制疾病或情况的发展；减轻疾病或症状；使疾病或症状减退；减轻由疾病或症状引起的并发症，或预防或治疗由疾病或症状引起的征兆。如本文所用，某一化合物或药物组合物，给药后，可以使某一疾病、症状或情况得到改善，尤指其严重度得到改善，延迟发病，减缓病情进展，或减少病情持续时间。无论固定给药或临时给药、持续给药或间歇给药，可以归因于或与给药有关的情况。
“活性成分”指通式(1)所示化合物，以及通式(1)化合物的药学上可接受的无机或有机盐。本发明的化合物可以含有一个或多个不对称中心(手性中心或轴手性)，并因此以消旋体、外消旋混合物、单一对映体、非对映异构体化合物和单一非对映体的形式出现。可以存在的不对称中心，取决于分子上各种取代基的性质。每个这种不对称中心将独立地产生两个旋光异构体，并且所有可能的旋光异构体和非对映体混合物以及纯或部分纯的化合物包括在本发明的范围之内。本发明意味着包括这些化合物的所有这种异构形式。
“化合物(compound)”、“组合物(composition)”、“药剂(agent)”或“医药品(medicine or medicament)”等词在此可交替使用，且都是指当施用于个体(人类或动物)时，能够透过局 部和/或全身性作用而诱发所亟求的药学和/或生理反应的一种化合物或组合物。
“施用(administered、administering或、administration)”一词在此是指直接施用所述的化合物或组合物，或施用活性化合物的前驱药(prodrug)、衍生物(derivative)、或类似物(analog)等。
虽然用以界定本发明较广范围的数值范围与参数皆是约略的数值，此处已尽可能精确地呈现具体实施例中的相关数值。然而，任何数值本质上不可避免地含有因个别测试方法所致的标准偏差。在此处，“约”通常是指实际数值在一特定数值或范围的正负10％、5％、1％或0.5％之内。或者是，“约”一词代表实际数值落在平均值的可接受标准误差之内，视本领域技术人员的考虑而定。除了实验例之外，或除非另有明确的说明，当可理解此处所用的所有范围、数量、数值与百分比(例如用以描述材料用量、时间长短、温度、操作条件、数量比例及其它相似者)均经过“约”的修饰。因此，除非另有相反的说明，本说明书与附随权利要求书所揭示的数值参数皆为约略的数值，且可视需求而更动。至少应将这些数值参数理解为所指出的有效位数与采用一般进位法所得到的数值。
除非本说明书另有定义，此处所用的科学与技术词汇的含义与本领域技术人员所理解的惯用的意义相同。此外，在不和上下文冲突的情形下，本说明书所用的单数名词涵盖该名词的复数型；而所用的复数名词时亦涵盖该名词的单数型。
治疗用途
本发明提供了使用本发明通式(1)化合物或药物组合物治疗疾病的方法，包括但不限于涉及EGFR突变的病况(例如癌症)。
在一些实施例中，提供了用于癌症治疗的方法，该方法包括给予有需要的个体有效量的任何前述的包括结构通式(1)化合物的药物组合物。在一些实施例中，癌症由EGFR突变介导。在其它实施例中，该癌症是乳腺癌、肺癌、胰腺癌、结肠癌、膀胱癌、脑癌、尿路上皮癌、前列腺癌、肝癌、卵巢癌、头颈癌、胃癌、间皮瘤或所有癌症转移。
给药途径
本发明的化合物及其药学上可接受的盐可制成各种制剂，其中包含安全、有效量范围内的本发明化合物或其药学上可接受的盐及药理上可以接受的赋形剂或载体。其中“安全、有效量”指的是：化合物的量足以明显改善病情，而不至于产生严重的副作用。化合物的安全、有效量根据治疗对象的年龄、病情、疗程等具体情况来确定。
“药学上可以接受的赋形剂或载体”指的是：一种或多种相容性固体或液体填料或凝胶物质，它们适合于人使用，而且必须有足够的纯度和足够低的毒性。“相容性”在此指的 是组合物中各组份能与本发明的化合物以及它们之间相互掺和，而不明显降低化合物的药效。药理上可以接受的赋形剂或载体部分例子有纤维素及其衍生物(如羧甲基纤维素钠、乙基纤维素钠、纤维素乙酸酯等)、明胶、滑石、固体润滑剂(如硬脂酸、硬脂酸镁)、硫酸钙、植物油(如豆油、芝麻油、花生油、橄榄油等)、多元醇(如丙二醇、甘油、甘露醇、山梨醇等)、乳化剂(如吐温
Figure PCTCN2021103366-appb-000079
)、润湿剂(如十二烷基硫酸钠)、着色剂、调味剂、稳定剂、抗氧化剂、防腐剂、无热原水等。
施用本发明化合物时，可以口服、直肠、肠胃外(静脉内、肌肉内或皮下)、局部给药。
用于口服给药的固体剂型包括胶囊剂、片剂、丸剂、散剂和颗粒剂。在这些固体剂型中，活性化合物与至少一种常规惰性赋形剂(或载体)混合，如柠檬酸钠或磷酸二钙，或与下述成分混合：(a)填料或增容剂，例如，淀粉、乳糖、蔗糖、葡萄糖、甘露醇和硅酸；(b)粘合剂，例如，羟甲基纤维素、藻酸盐、明胶、聚乙烯基吡咯烷酮、蔗糖和阿拉伯胶；(c)保湿剂，例如，甘油；(d)崩解剂，例如，琼脂、碳酸钙、马铃薯淀粉或木薯淀粉、藻酸、某些复合硅酸盐、和碳酸钠；(e)缓溶剂，例如石蜡；(f)吸收加速剂，例如，季胺化合物；(g)润湿剂，例如鲸蜡醇和单硬脂酸甘油酯；(h)吸附剂，例如，高岭土；和(i)润滑剂，例如，滑石、硬脂酸钙、硬脂酸镁、固体聚乙二醇、十二烷基硫酸钠，或其混合物。胶囊剂、片剂和丸剂中，剂型也可包含缓冲剂。
固体剂型如片剂、糖丸、胶囊剂、丸剂和颗粒剂可采用包衣和壳材制备，如肠衣和其它本领域公知的材料。它们可包含不透明剂，并且，这种组合物中活性化合物或化合物的释放可以延迟的方式在消化道内的某一部分中释放。可采用的包埋组分的实例是聚合物质和蜡类物质。必要时，活性化合物也可与上述赋形剂中的一种或多种形成微胶囊形式。
用于口服给药的液体剂型包括药学上可接受的乳液、溶液、悬浮液、糖浆或酊剂。除了活性化合物外，液体剂型可包含本领域中常规采用的惰性稀释剂，如水或其它溶剂，增溶剂和乳化剂，例知，乙醇、异丙醇、碳酸乙酯、乙酸乙酯、丙二醇、1，3-丁二醇、二甲基甲酰胺以及油，特别是棉籽油、花生油、玉米胚油、橄榄油、蓖麻油和芝麻油或这些物质的混合物等。
除了这些惰性稀释剂外，组合物也可包含助剂，如润湿剂、乳化剂和悬浮剂、甜味剂、矫味剂和香料。
除了活性化合物外，悬浮液可包含悬浮剂，例如，乙氧基化异十八烷醇、聚氧乙烯山梨醇和脱水山梨醇酯、微晶纤维素、甲醇铝和琼脂或这些物质的混合物等。
用于肠胃外注射的组合物可包含生理上可接受的无菌含水或无水溶液、分散液、悬浮液或乳液，和用于重新溶解成无菌的可注射溶液或分散液的无菌粉末。适宜的含水和非水载体、稀释剂、溶剂或赋形剂包括水、乙醇、多元醇及其适宜的混合物。
用于局部给药的本发明化合物的剂型包括软膏剂、散剂、贴剂、喷射剂和吸入剂。活性成分在无菌条件下与生理上可接受的载体及任何防腐剂、缓冲剂，或必要时可能需要的推进剂一起混合。
本发明化合物可以单独给药，或者与其他药学上可接受的化合物联合给药。使用药物组合物时，是将安全有效量的本发明化合物适用于需要治疗的哺乳动物(如人)，其中施用时剂量为药学上认为的有效给药剂量，对于60kg体重的人而言，日给药剂量通常为1～2000mg，优选50～1000mg。当然，具体剂量还应考虑给药途径、病人健康状况等因素，这些都是熟练医师技能范围之内的。
本发明提到的上述特征，或实施例提到的特征可以任意组合。本案说明书所揭示的所有特征可与任何组合物形式并用，说明书中所揭示的各个特征，可以任何可提供相同、均等或相似目的的替代性特征取代。因此除有特别说明，所揭示的特征仅为均等或相似特征的一般性例子。
具体实施方式
在下面的说明中将会详细阐述上述化合物、方法、药物组合物的各个具体方面、特性和优势，使本发明的内容变得十分明了。在此应理解，下述的详细说明及实例描述了具体的实施例，仅用于参考。在阅读了本发明的说明内容后，本领域的技术人员可对本发明作各种改动或修改，这些等价形势同样落于本申请所限定的范围。
所有实施例中， 1H-NMR用Varian Mercury 400核磁共振仪记录，化学位移以δ(ppm)表示；分离用硅胶未说明均为200-300目，洗脱液的配比均为体积比。
本发明采用下述缩略词：CDCl 3代表氘代氯仿；EtOH代表乙醇；MeOH代表甲醇；Hexane代表正己烷；DCM代表二氯甲烷；DIPEA代表二异丙基乙基胺；Dioxane代表1，4-二氧六环；DMF代表N，N-二甲基甲酰胺；DMSO代表二甲亚砜；THF代表四氢呋喃；TEA代表三乙胺；EDCI代表N-(3-二甲基氨基丙基)-N′-乙基碳二亚胺；HOBt代表1-羟基苯并三氮唑；K 3PO 4代表磷酸钾；NaHCO 3代表碳酸氢钠；K 2CO 3代表碳酸钾；m-CPBA代表间氯过氧苯甲酸；Pd/C代表钯碳；LiOH代表氢氧化锂；Pd(dppf)Cl 2代表[1，1′-双(二苯基膦基)二茂铁]二氯化钯；NaH代表氢化钠；NMP代表1-甲基吡咯烷-2-酮；POCl 3代表三氯氧磷；8OCl 2代表二氯亚砜；TFA(CF 3COOH)代表三氟乙酸；NMR代表核磁共振； MS代表质谱；TLC代表薄层色谱；h代表小时；min代表分钟。
合成方法A：
使用合成方法A进行具体实施例1：N-(1-(2-羟基-2-甲基丙基)-6-(4-(4-甲基哌嗪-1-基)哌啶-1-基)-1H-苯并[d]咪唑-2-基)-4′-甲氧基-6-甲基-[2，3′-联吡啶]-4-甲酰胺：
Figure PCTCN2021103366-appb-000080
步骤1：4′-甲氧基-6-甲基-[2，3′-联吡啶]-4-羧酸甲酯(化合物int_2)的合成：
将4-甲氧基-3-(4，4，5，5-四甲基-1，3，2-二氧硼戊环-2-基)吡啶(2.35g，10mmol)，2-氯-6-甲基异烟酸甲酯(1.85g，10mmol)，Pd(dppf)Cl 2(732mg，1mmol)，溶于1，4-二氧六环中(50mL)，加入碳酸钾(4.0M，20mmol，5mL)，氩气保护下，升温80℃反应过夜，LC-MS监测反应完毕，加入乙酸乙酯(150mL)，水(100mL)，分液，有机相浓缩，柱层析得到棕色固体2.1g，收率81％。
ESI-MS m/z：259[M+H] +.
步骤2：4′-甲氧基-6-甲基-[2，3′-联吡啶]-4-羧酸(化合物int_3)的合成：
将4′-甲氧基-6-甲基-[2，3′-联吡啶]-4-羧酸甲酯(2.0g，7.7mmol)溶于甲醇、四氢呋喃和 水的混合溶剂(1∶1∶1，15mL)中，加入氢氧化锂水合物(1.96g，46.5mmol)，室温搅拌反应3h，LC-MS监测反应完毕，冰浴下浓盐酸调pH至约5～6，析出固体，过滤，滤饼干燥，得到浅黄色固体1.0g，收率53％。
ESI-MS m/z：245[M+H] +.
步骤3：1-((5-氟-2-硝基苯基)氨基)-2-甲基丙烷-2-醇(化合物int_5)的合成：
将1-氨基-2-甲基丙烷-2-醇(5.88g，66mmol)，2，4-二氟-1-硝基苯(10g，62.8mmol)溶于DMF(300mL)中，加入DIPEA(24.33g，188.6mmol)，于60℃反应3h，LC-MS监测反应完毕，直接浓缩柱层析得到黄色固体12g，收率83％。
ESI-MS m/z：229[M+H] +.
步骤4：1-甲基-1-((5-(4-(4-甲基哌嗪-1-基)哌啶-1-基)-2-硝基苯基)氨基)丙烷-2-醇(化合物int_6)的合成：
将1-((5-氟-2-硝基苯基)氨基)-2-甲基丙烷-2-醇(3g，13.15mmol)，1-甲基-4-(哌啶-4-基)哌嗪(2.41g，13.15mmol)溶于DMF(60mL)中，加入碳酸钾(3.63g，26.29mmol)，于120℃反应6h，LC-MS监测反应完毕，过滤，有机相浓缩，柱层析得到棕色固体4g，收率78％。
ESI-MS m/z：392[M+H] +.
步骤5：1-((2-氨基-5-(4-(4-甲基哌嗪-1-基)哌啶-1-基)苯基)氨基)-2-甲基丙烷-2-醇(化合物int_7)的合成：
将1-甲基-1-((5-(4-(4-甲基哌嗪-1-基)哌啶-1-基)-2-硝基苯基)氨基)丙烷-2-醇(4g，10.22mmol)溶于甲醇、四氢呋喃混合液(1∶1，300mL)中，加入Pd/C(800mg)，通入氢气，室温反应过夜，LC-MS监测反应完毕，过滤，有机相浓缩，得到棕色固体3.2g，收率86％。
ESI-MS m/z：362[M+H] +.
步骤6：1-(2-氨基-6-(4-(4-甲基哌嗪-1-基)哌啶-1-基)-1H-苯并[d]咪唑-1-基)-2-甲基丙烷-2-醇(化合物int_8)的合成：
将1-((2-氨基-5-(4-(4-甲基哌嗪-1-基)哌啶-1-基)苯基)氨基)-2-甲基丙烷-2-醇(1g，2.77mmol)溶于二氯甲烷(20mL)和乙醇(20mL)的混合溶剂中，冰浴，滴加溴化氰的二氯甲烷(4mL)溶液，室温搅拌反应过夜，LC-MS监测反应完毕，有机相浓缩，直接反相柱层析， 得到浅黄色固体320mg，收率30％。
ESI-MS m/z：387[M+H] +.
步骤7：N-(1-(2-羟基-2-甲基丙基)-6-(4-(4-甲基哌嗪-1-基)哌啶-1-基)-1H-苯并[d]咪唑-2-基)-4′-甲氧基-6-甲基-[2，3′-联吡啶]-4-甲酰胺(化合物1)的合成：
将1-(2-氨基-6-(4-(4-甲基哌嗪-1-基)哌啶-1-基)-1H-苯并[d]咪唑-1-基)-2-甲基丙烷-2-醇(100mg，0.26mmol)，4′-甲氧基-6-甲基-[2，3′-联吡啶]-4-羧酸(63mg，0.26mmol)，TEA(131mg，1.29mmol)，HOBt(52mg，0.39mol)溶于DMF(5mL)中，加入EDCI(75mg，0.39mmol)，室温反应过夜，LC-MS监测反应完毕，制备液相色谱纯化，得到浅黄色固体10mg，收率7％。
1H NMR(400MHz，CDCl 3)δ：8.87(s，1H)，8.51(d，J＝5.8Hz，1H)，8.27(s，1H)，7.82(d，J＝1.4Hz，1H)，7.24(d，J＝7.3Hz，2H)，6.96-6.90(m，2H)，6.83(d，J＝2.1Hz，1H)，5.38-5.24(m，1H)，4.23(s，2H)，3.96(s，3H)，3.69(d，J＝12.2Hz，2H)，3.30-2.95(m，6H)，2.78(t，J＝11.9Hz，3H)，2.68(d，J＝12.0Hz，6H)，2.03-1.95(m，2H)，1.85-1.60(m，4H)，1.34(s，6H)；ESI-MS m/z：613[M+H] +.
合成方法B：
使用合成方法B进行具体实施例2：3-氟-N-(1-(2-羟基-2-甲基丙基)-5-(4-(4-甲基哌嗪-1-基)哌啶-1-基)-1H-苯并[d]咪唑-2-基)-4′-甲氧基-6-甲基-[2，3′-联二吡啶]-4-甲酰胺的合成：
Figure PCTCN2021103366-appb-000081
步骤1：2-溴-5-氟异烟酸甲酯(化合物int_2)的合成：
往1L单口瓶中加入2-溴-5-氟异烟酸(14g，63.64mmol)和MeOH(200mL)，冷却至0-5℃，分批加入8OCl 2(37.85g，318.19mmol)后，室温反应过夜。反应液浓缩得到固体，将固体溶解于水中，用饱和NaHCO 3调pH值至9，水相用用乙酸乙酯(1000mL*2)萃取，合并有机相，有机相用食盐水洗，无水硫酸钠干燥，过滤，浓缩得白色固体(13.8g，收率：92.6％)。
ESI-MS m/z：233[M+H] +.
步骤2：5-氟-2-甲基异烟酸甲酯(化合物int_3)的合成：
往100mL单口瓶中加入2-溴-5-氟异烟酸甲酯(13.8g，58.97mmol)，Pd(dppf)Cl 2(2.16g，2.95mmol)，碳酸钾(16.30g，117.94mmol)，三甲基硼氧六环(14.81g，117.94mmol)和Dioxane(150mL)，氮气保护下90℃反应过夜。反应液过滤，滤液浓缩得到粗品。粗品经过柱层析纯化得白色固体产物(9.90g，收率：99％)。
ESI-MS m/z：170[M+H] +.
步骤3：5-氟-4-(甲氧基羰基)-2-甲基吡啶1-氧化物(化合物int_4)的合成：
往500mL单口瓶中加入5-氟-2-甲基异烟酸甲酯(9.90g，58.53mmol)，m-CPBA(20.20g，117.05mmol)和DCM(150mL)，加完25℃搅拌2h，反应液减压浓缩得到粗品。粗品经柱层析纯化得到黄色固体产物(8.50g，收率：78.4％)。
ESI-MS m/z：186[M+H] +.
步骤4：2-氯-3-氟-6-甲基异烟酸甲酯(化合物int_5)的合成：
往250mL单口瓶中加入5-氟-4-(甲氧基羰基)-2-甲基吡啶1-氧化物(8.50g，45.91mmol)和POCl 3(126mL)，80℃反应2h。将反应液减压浓缩，水相用DCM(100mL*3)萃取，合并有机相，有机相用食盐水洗，无水硫酸钠干燥，过滤，浓缩得粗品，粗品经柱层析纯化得到黄色固体产物(5.20g，收率：25.54％)。
ESI-MS m/z：204[M+H] +.
步骤5：3-氟-4′-甲氧基-6-甲基-[2，3′-联二吡啶]-4-羧酸甲酯(化合物int_6)的合成：
将4-甲氧基-3-(4，4，5，5-四甲基-1，3，2-二氧硼戊环-2-基)吡啶(3.60g，17.68mmol)，2-氯-3-氟-6-甲基异烟酸甲酯(3.00g，14.73mmol)，Pd(dppf)Cl 2(539.08mg，0.74mmol)，溶于1，4-二氧六环中(20mL)，加入碳酸钾(4.07g，29.47mmol)，氩气保护下，升温80℃反应过夜，LC-MS监测反应完毕，加入乙酸乙酯(150mL)，水(100mL)，分液，有机相浓缩，柱层析得到棕色固体3.0g，收率73.7％。
ESI-MS m/z：277[M+H] +.
步骤6：3-氟-4′-甲氧基-6-甲基-[2，3′-联二吡啶]-4-羧酸(化合物int_7)的合成：
将3-氟-4′-甲氧基-6-甲基-[2，3′-联二吡啶]-4-羧酸甲酯(3.00g，10.86mmol)溶于甲醇、四氢呋喃和水的混合溶剂(1∶1∶1，15mL)中，加入氢氧化锂水合物(2.73g，65.16mmol)， 室温搅拌反应2h，LC-MS监测反应完毕，加入水(30mL)，水相用DCM(200mL*3)萃取，弃去有机相，水相在冰浴下用浓盐酸调pH至约5～6，水相用DCM(200mL*3)萃取，合并有机相，有机相用食盐水洗，无水硫酸钠干燥，过滤，浓缩得粗品，粗品经在乙醇中重结晶得到灰色固体产物(630mg，收率：17.4％)。
1H NMR(400MHz，DMSO-d6)δ：8.58(d，J＝5.8Hz，1H)，8.39(s，1H)，7.67(d，J＝5.0Hz，1H)，7.24(d，J＝6.0Hz，1H)；ESI-MS m/z：263[M+H] +.
步骤7：1-((4-氟-2-硝基苯基)氨基)-2-甲基丙基-2-醇(化合物int_9)的合成：
将1-氨基-2-甲基丙烷-2-醇(5.88g，66mmol)，1，4-二氟-2-硝基苯(10g，62.8mmol)溶于DMF(300mL)中，加入DIPEA(24.33g，188.6mmol)，于60℃反应3h，LC-MS监测反应完毕，直接浓缩柱层析得到黄色固体10g，收率70％。
ESI-MS m/z：229[M+H] +.
步骤8：2-甲基l-1-((4-(4-(4-甲基哌嗪-1-基)哌啶-1-基)-2-硝基苯基)氨基)丙基-2-醇(化合物int_10)的合成：
将1-((4-氟-2-硝基苯基)氨基)-2-甲基丙基-2-醇(3g，13.15mmol)，1-甲基-4-(哌啶-4-基)哌嗪(2.41g，13.15mmol)溶于DMF(60mL)中，加入碳酸钾(3.63g，26.29mmol)，于120℃反应6h，LC-MS监测反应完毕，过滤，有机相浓缩，柱层析得到棕色固体4.1g，收率80.3％。
ESI-MS m/z：392[M+H] +.
步骤9：1-((2-氨基-4-(4-(4-甲基哌嗪-1-基)哌啶-1-基)苯基)氨基)-2-甲基丙基-2-醇(化合物int_11)的合成：
将2-甲基l-1-((4-(4-(4-甲基哌嗪-1-基)哌啶-1-基)-2-硝基苯基)氨基)丙基-2-醇(4g，10.22mmol)溶于甲醇、四氢呋喃混合液(1∶1，300mL)中，加入Pd/C(800mg)，通入氢气，室温反应过夜，LC-MS监测反应完毕，过滤，有机相浓缩，得到棕色固体3.0g，收率81.3％。
ESI-MS m/z：362[M+H] +.
步骤10：1-(2-氨基-5-(4-(4-甲基哌嗪-1-基)哌啶-1-基)-1H-苯并[d]咪唑-1-基)-2-甲基丙基- 2-醇(化合物int_12)的合成：
将1-((2-氨基-4-(4-(4-甲基哌嗪-1-基)哌啶-1-基)苯基)氨基)-2-甲基丙基-2-醇(1g，2.77mmol)溶于二氯甲烷(20mL)和乙醇(20mL)的混合溶剂中，冰浴，滴加溴化氰的二氯甲烷(4mL)溶液，室温搅拌反应过夜，LC-MS监测反应完毕，有机相浓缩，直接反相柱层析，得到浅黄色固体300mg，收率28％。
ESI-MS m/z：387[M+H] +.
步骤11：3-氟-N-(1-(2-羟基-2-甲基丙基)-5-(4-(4-甲基哌嗪-1-基)哌啶-1-基)-1H-苯并[d]咪唑-2-基)-4′-甲氧基-6-甲基-[2，3′-联二吡啶]-4-甲酰胺(化合物2)的合成：
将1-(2-氨基-5-(4-(4-甲基哌嗪-1-基)哌啶-1-基)-1H-苯并[d]咪唑-1-基)-2-甲基丙基-2-醇(100mg，0.26mmol)，3-氟-4′-甲氧基-6-甲基-[2，3′-联二吡啶]-4-羧酸(68mg，0.26mmol)，TEA(131mg，1.29mmol)，HOBt(52mg，0.39mol)溶于DMF(5mL)中，加入EDCI(75mg，0.39mmol)，室温反应过夜，LC-MS监测反应完毕，制备液相色谱纯化，得到浅黄色固体15mg，收率9.2％。
ESI-MS m/z：631[M+H] +.
实施例1化合物3-332的合成
使用合成方法A或合成方法B，采用不同原料，可以得到表1中目标化合物3-332。
表1
Figure PCTCN2021103366-appb-000082
Figure PCTCN2021103366-appb-000083
Figure PCTCN2021103366-appb-000084
Figure PCTCN2021103366-appb-000085
Figure PCTCN2021103366-appb-000086
Figure PCTCN2021103366-appb-000087
Figure PCTCN2021103366-appb-000088
Figure PCTCN2021103366-appb-000089
Figure PCTCN2021103366-appb-000090
Figure PCTCN2021103366-appb-000091
Figure PCTCN2021103366-appb-000092
Figure PCTCN2021103366-appb-000093
Figure PCTCN2021103366-appb-000094
Figure PCTCN2021103366-appb-000095
Figure PCTCN2021103366-appb-000096
Figure PCTCN2021103366-appb-000097
Figure PCTCN2021103366-appb-000098
实施例2本发明化合物对EGFR(del19/T790M/C797S)、EGFR(L858R/T790M/C797S)或EGFR(WT)酶的抑制活性的检测
运用HTRF方法测定化合物对EGFR(del19/T790M/C797S)、EGFR(L858R/T790M/C797S)或EGFR(WT)酶活的抑制作用。具体如下：
将WT或者突变型EGFR蛋白与梯度稀释的化合物在28℃孵育10分钟后加入biotin-标记的通用酪氨酸激酶底物(TK)和ATP，在室温反应40分钟。终止反应后加入针对TK的Eu3+-Cryptate标记抗体和streptavidin-XL665，在室温孵育60分钟。通过检测615nm和665nm的发光，计算665/615的比值，定量TK底物磷酸化的水平。与对照组相比，计算化合物抑制百分比和IC50。结果见下列表2。
表2.本发明化合物对EGFR(del19/T790M/C797S)、EGFR(L858R/T790M/C797S)或EGFR(WT)的抑制活性
Figure PCTCN2021103366-appb-000099
Figure PCTCN2021103366-appb-000100
+表示抑制率小于或等于20％
++表示抑制率为20％至50％
+++表示抑制率大于50％。
N.D表示活性未测
从表2数据可知，本发明化合物对EGFR(del19/T790M/C797S)和EGFR(L858R/T790M/C797S)的酶活性有较好的抑制活性，且对EGFR(WT)有较好的选择性。
实施例3本发明化合物对Ba/F3(EGFR del19/T790M/C797S)三突变细胞和A431(EGFR WT)细胞的抗增殖活性
3000个携带EGFR(del19/T790M/C797S)的Ba/F3细胞，或者2000个A431细胞种植于384孔板中，生长一天后，加入梯度稀释的化合物(Ba/F3细胞最高500nM，A431细胞最高10uM)。加入化合物三天后，加入Cell Titer Glow评价细胞生长，计算化合物抑制细胞生长的百分率和IC 50值，结果见下列表3。
表3.本发明化合物对Ba/F3(EGFR del19/T790M/C797S)三突变细胞和A431野生型(EGFRWT)细胞的抗增殖活性
Figure PCTCN2021103366-appb-000101
从表3数据可知，本发明绝大多数化合物对Ba/F3(EGFR del19/T790M/C797S)三突变细胞的抗增殖活性都小于200nM，可见当R 2、R 5或R 6为如上文所定义基团时，化合物都具有很强的Ba/F3(EGFR del19/T790M/C797S)三突变细胞的抗增殖活性。

Claims (17)

  1. 一种如通式(1)所示的化合物或其各异构体、各晶型、药学上可接受的盐、水合物或溶剂合物：
    Figure PCTCN2021103366-appb-100001
    通式(1)中：
    R 1为(C3-C6)烷基、(C3-C6)环烷基或(4-7元)杂环烷基，其中所述(C3-C6)烷基、(C3-C6)环烷基、(4-7元)杂环烷基各自独立任选被1个或多个下列基团取代：-H、-OH、卤素、(C1-C6)烷基和(C1-C6)烷氧基；
    R 2为-H或者卤素；
    R 3为-H、卤素、-CN、-NH 2、-NR 3aR 3b、(C1-C4)烷基、(C1-C4)卤代烷基、(C2-C4)烯基或(C2-C4)炔基；
    R 4为苯基、(5-6元)杂芳基或9元杂芳基，其中所述苯基、(5-6元)杂芳基或9元杂芳基各自独立任选被1个或多个下列基团取代：-H、卤素、-OH、-CN、(C1-C6)烷基、(C3-C6)环烷基、(C1-C6)卤代烷基、-O-(C1-C6)烷基、-O-(C3-C6)环烷基、-O-(C1-C6)卤代烷基、-NR 4aR 4b、-C(O)NHR 4aR 4b和-(CH 2) mNR 4aR 4b；
    当R 2为-H时，R 5为-(CH 2) n-(3-11元)杂环烷基、-O-(CH 2) m-(4-9元)杂环烷基、-O-(CH 2) m-NR 5aR 5b、(C1-C6)烷氧基或(C1-C6)卤代烷氧基，其中所述(3-11元)杂环烷基各自独立被1个或多个下列基团取代：-R 5c、-(CH 2) m-NR 5aR 5b、-N(R 4a)-(CH 2) m-NR 5aR 5b、-O-(CH 2) m-NR 5aR 5b和-O-(CH 2) m-OR 5a，和其中所述(4-9元)杂环烷基、(C1-C6)烷氧基或(C1-C6)卤代烷氧基各自独立任选被1个或多个下列基团取代：-H、-CN、-OH、(C1-C6)烷基、-(C1-C6)环烷基、-NR 5aR 5b和卤素；
    当R 2为卤素时，R 5为-H、卤素、-(CH 2) n-(3-11元)杂环烷基、-O-(CH 2) m-(4-9元)杂环烷基、-O-(CH 2) m-NR 5aR 5b、(C1-C6)烷氧基、(C1-C6)卤代烷氧基、-NR 5aR 5b、-N(R 4a)-(CH 2) m-NR 5aR 5b或(C1-C6)烷基，其中所述(3-11元)杂环烷基各自独立任选被1个或多个下列基团取代：(C1-C4)烷基、(C1-C4)烷氧基、(C3-C6)环烷基、-NR 5aR 5b、-(CH 2) m-NR 5aR 5b、-(CH 2) m- OR 5a、-N(R 4a)-(CH 2) m-NR 5aR 5b、-O-(CH 2) m-NR 5aR 5b和-O-(CH 2) m-OR 5a和-R 5c，和其中所述(4-9元)杂环烷基、(C1-C6)烷氧基、(C1-C6)烷基或(C1-C6)卤代烷氧基各自独立任选被1个或多个下列基团取代：-H、-CN、-OH、(C1-C6)烷基、-(C1-C6)环烷基、-NR 5aR 5b和卤素；
    R 6为-H、卤素、-(CH 2) n-(3-11元)杂环烷基、-O-(CH 2) m-(4-9元)杂环烷基、-O-(CH 2) m-NR 5aR 5b、(C1-C6)烷氧基、(C1-C6)卤代烷氧基、-NR 5aR 5b、-N(R 4a)-(CH 2) m-NR 5aR 5b或(C1-C6)烷基，其中所述(3-11元)杂环烷基各自独立任选被1个或多个下列基团取代：(C1-C4)烷基、(C1-C4)烷氧基、(C3-C6)环烷基、-NR 5aR 5b、-(CH 2) m-NR 5aR 5b、-(CH 2) m-OR 5a、-N(R 4a)-(CH 2) m-NR 5aR 5b、-O-(CH 2) m-NR 5aR 5b和-O-(CH 2) m-OR 5a和-R 5c，和其中所述(4-9元)杂环烷基、(C1-C6)烷氧基、(C1-C6)卤代烷氧基或(C1-C6)烷基各自独立任选被1个或多个下列基团取代：-H、-CN、-OH、(C1-C6)烷基、-(C1-C6)环烷基、-NR 5aR 5b和卤素；
    R 7为-H或者卤素；
    R 3a和R 3b各自独立地为-H或(C1-C4)烷基；
    R 4a和R 4b各自独立地为-H或(C1-C6)烷基；
    R 5a和R 5b各自独立地为-H、(C1-C6)烷基或(C3-C6)环烷基，或R 5a和R 5b与其连接的N原子能够共同组成一个(3-11元)杂环烷基，此杂环烷基各自独立任选被1个或多个下列基团取代：-H、-(C1-C6)烷基和卤素；
    R 5c为(3-11元)杂环烷基，此杂环烷基各自独立任选被1个或多个下列基团取代：-H、-(C1-C6)烷基、-(C1-C6)环烷基、卤素和-CD3；
    m为1或2的整数；和
    n为0、1或2的整数。
  2. 如权利要求1所述的化合物或其各异构体、各晶型、药学上可接受的盐、水合物或溶剂合物，其中所述通式(1)中，R 1为(C3-C6)烷基、(C3-C6)环烷基或(4-7元)杂环烷基，其中所述(C3-C6)烷基、(C3-C6)环烷基、(4-7元)杂环烷基各自独立任选被1个或多个下列基团取代：-H、-OH、-F、-CH 3和-OCH 3。
  3. 如权利要求2所述的化合物或其各异构体、各晶型、药学上可接受的盐、水合物或溶剂合物，其中所述通式(1)中，R 1为：
    Figure PCTCN2021103366-appb-100002
  4. 如权利要求1-3中任一项所述的化合物或其各异构体、各晶型、药学上可接受的盐、水合物或溶剂合物，其中所述通式(1)中，R 2为-H或者-F。
  5. 如权利要求1-4中任一项所述的化合物或其各异构体、各晶型、药学上可接受的盐、水合物或溶剂合物，其中所述通式(1)中，R 3为-H、-F、-CN、-NH 2、-N(CH 3) 2、-CH 3、-CH 2CH 3、-CF 3、-CHF 2或-C≡CH。
  6. 如权利要求1-5中任一项所述的化合物或其各异构体、各晶型、药学上可接受的盐、水合物或溶剂合物，其中所述通式(1)中，R 4为苯基、(5-6元)杂芳基或9元杂芳基，其中所述苯基、(5-6元)杂芳基或9元杂芳基各自独立任选被1个或多个下列基团取代：-H、-F、-Cl、-OH、-CN、-CH 3、-OCH 3、-N(CH 3) 2、和-NH 2。
  7. 如权利要求6所述的化合物或其各异构体、各晶型、药学上可接受的盐、水合物或溶剂合物，其中所述通式(1)中，R 4为：
    Figure PCTCN2021103366-appb-100003
  8. 如权利要求1-7中任一项所述的化合物或其各异构体、各晶型、药学上可接受的盐、水合物或溶剂合物，其中所述通式(1)中，R 2为-H，和R 5为(4-10元)杂环烷基、-(CH 2)-(4-10元)杂环烷基、-O-(CH 2)-(4-9元)杂环烷基、-O-(CH 2) 2-(4-9元)杂环烷基、-O-(CH 2) 2-N(CH 3) 2、-O-(CH 2) 2-N(CH 2CH 3) 2或-OCH 3，其中所述(4-10元)杂环烷基为：
    Figure PCTCN2021103366-appb-100004
    Figure PCTCN2021103366-appb-100005
    所述此(4-10元)杂环烷基各自独立被1个或多个下列基团取代：
    Figure PCTCN2021103366-appb-100006
    Figure PCTCN2021103366-appb-100007
    Figure PCTCN2021103366-appb-100008
    和其中所述(4-9元)杂环烷基为：
    Figure PCTCN2021103366-appb-100009
    Figure PCTCN2021103366-appb-100010
    所述此(4-9元)杂环烷基各自独立被1个或多个下列基团取代：-H、-F、-CH 3、-CN、
    Figure PCTCN2021103366-appb-100011
    -OH、-OCH 3和-N(CH 3) 2。
  9. 如权利要求8所述的化合物或其各异构体、各晶型、药学上可接受的盐、水合物或溶剂合物，其中所述通式(1)中，R 2为-H，和R 5为：
    -OCH 3、-O-(CH 2) 2-N(CH 3) 2、-O-(CH 2) 2-N(CH 2CH 3) 2、
    Figure PCTCN2021103366-appb-100012
    Figure PCTCN2021103366-appb-100013
    Figure PCTCN2021103366-appb-100014
  10. 如权利要求1-7中任一项所述的化合物或其各异构体、各晶型、药学上可接受的盐、水合物或溶剂合物，其中所述通式(1)中，R 2为-F，和R 5为-H、-F、-Cl、(4-10元)杂环烷基、-(CH 2)-(4-10元)杂环烷基、-O-(CH 2)-(4-9元)杂环烷基、-O-(CH 2) 2-(4-9元)杂环烷基、-O-(CH 2) 2-N(CH 3) 2、-O-(CH 2) 2-N(CH 2CH 3) 2、-OCH 3、-N(CH 2CH 3) 2、-NH-(CH 2) 2-N(CH 3) 2、-N(CH 3)-(CH 2) 2-N(CH 3) 2或(C1-C6)烷基，其中所述(4-10元)杂环烷基为：
    Figure PCTCN2021103366-appb-100015
    Figure PCTCN2021103366-appb-100016
    所述此(4-10元)杂环烷基各自独立任选被1个或多个下列基团取代：-H、-F、-CH 3、-CN、
    Figure PCTCN2021103366-appb-100017
    -OH、-OCH 3、-N(CH 3) 2、
    Figure PCTCN2021103366-appb-100018
    Figure PCTCN2021103366-appb-100019
    Figure PCTCN2021103366-appb-100020
    和其中所述(4-9元)杂环烷基为：
    Figure PCTCN2021103366-appb-100021
    Figure PCTCN2021103366-appb-100022
    Figure PCTCN2021103366-appb-100023
    所述此(4-9元)杂环烷基各自独立任选被1个或多个下列基团取代：-H、-F、-CH 3、-CN、
    Figure PCTCN2021103366-appb-100024
    -OH、-OCH 3和-N(CH 3) 2。
  11. 如权利要求10所述的化合物或其各异构体、各晶型、药学上可接受的盐、水合物或溶剂合物，其中所述通式(1)中，R 2为-F，和R 5为：-H、-F、-Cl、-OCH 3、-N(CH 3) 2、-O- (CH 2) 2-N(CH 3) 2、-O-(CH 2) 2-N(CH 2CH 3) 2、-N(CH 2CH 3) 2、-NH-(CH 2) 2-N(CH 3) 2、-N(CH 3)-(CH 2) 2-N(CH 3) 2、
    Figure PCTCN2021103366-appb-100025
    Figure PCTCN2021103366-appb-100026
    Figure PCTCN2021103366-appb-100027
  12. 如权利要求1-11中任一项所述的化合物或其各异构体、各晶型、药学上可接受的盐、水合物或溶剂合物，其中所述通式(1)中，R 6为-H、-F、-Cl、(4-10元)杂环烷基、-(CH 2)-(4-10元)杂环烷基、-O-(CH 2)-(4-9元)杂环烷基、-O-(CH 2) 2-(4-9元)杂环烷基、-O-(CH 2) 2-N(CH 3) 2、-O-(CH 2) 2-N(CH 2CH 3) 2、-OCH 3、-N(CH 2CH 3) 2、-NH-(CH 2) 2-N(CH 3) 2、-N(CH 3)-(CH 2) 2-N(CH 3) 2或(C1-C6)烷基，其中所述(4-10元)杂环烷基为：
    Figure PCTCN2021103366-appb-100028
    Figure PCTCN2021103366-appb-100029
    所述此(4-10元)杂环烷基各自独立任选被1个或多个下列基团取代：-H、-F、-CH 3、-CN、
    Figure PCTCN2021103366-appb-100030
    -OH、-OCH 3、-N(CH 3) 2、
    Figure PCTCN2021103366-appb-100031
    Figure PCTCN2021103366-appb-100032
    Figure PCTCN2021103366-appb-100033
    和其中所述(4-9元)杂环烷基为：
    Figure PCTCN2021103366-appb-100034
    Figure PCTCN2021103366-appb-100035
    所述此(4-9元)杂环烷基各自独立任选被1个或多个下列基团取代：-H、-F、-CH 3、-CN、
    Figure PCTCN2021103366-appb-100036
    -OH、-OCH 3和-N(CH 3) 2。
  13. 如权利要求12所述的化合物或其各异构体、各晶型、药学上可接受的盐、水合物或溶剂合物，其中所述通式(1)中，R 6为：-H、-F、-Cl、-OCH 3、-N(CH 3) 2、-O-(CH 2) 2-N(CH 3) 2、-O-(CH 2) 2-N(CH 2CH 3) 2、-N(CH 2CH 3) 2、-NH-(CH 2) 2-N(CH 3) 2、-N(CH 3)-(CH 2) 2-N(CH 3) 2、
    Figure PCTCN2021103366-appb-100037
    Figure PCTCN2021103366-appb-100038
  14. 如权利要求1-13中任一项所述的化合物或其各异构体、各晶型、药学上可接受的盐、水合物或溶剂合物，其中所述通式(1)中，R 7为-H、-F或-Cl。
  15. 如权利要求1-14中任一项所述的化合物或其各异构体、各晶型、药学上可接受的盐、水合物或溶剂合物，其中所述化合物具有以下结构之一：
    Figure PCTCN2021103366-appb-100039
    Figure PCTCN2021103366-appb-100040
    Figure PCTCN2021103366-appb-100041
    Figure PCTCN2021103366-appb-100042
    Figure PCTCN2021103366-appb-100043
    Figure PCTCN2021103366-appb-100044
    Figure PCTCN2021103366-appb-100045
    Figure PCTCN2021103366-appb-100046
    Figure PCTCN2021103366-appb-100047
    Figure PCTCN2021103366-appb-100048
    Figure PCTCN2021103366-appb-100049
    Figure PCTCN2021103366-appb-100050
    Figure PCTCN2021103366-appb-100051
    Figure PCTCN2021103366-appb-100052
  16. 一种药物组合物，其特征在于，其含有药学上可接受的赋形剂或载体，以及如权利要求1-15中任一项所述的化合物、或其各异构体、各晶型、药学上可接受的盐、水合物或 溶剂合物作为活性成分。
  17. 一种如权利要求1-15中任一项所述的化合物、或其各异构体、各晶型、药学上可接受的盐、水合物或溶剂合物或如权利要求16所述的药物组合物用于制备治疗、调节或预防与EGFR突变相关疾病的药物中的应用；所述与EGFR突变相关疾病可为癌症；其中所述癌症可以是血液癌或实体瘤。
PCT/CN2021/103366 2020-07-01 2021-06-30 新型苯并咪唑化合物 WO2022002100A1 (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202180046799.6A CN115867542A (zh) 2020-07-01 2021-06-30 新型苯并咪唑化合物

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202010629495.XA CN113880804A (zh) 2020-07-01 2020-07-01 新型苯并咪唑化合物
CN202010629495.X 2020-07-01

Publications (1)

Publication Number Publication Date
WO2022002100A1 true WO2022002100A1 (zh) 2022-01-06

Family

ID=79012998

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2021/103366 WO2022002100A1 (zh) 2020-07-01 2021-06-30 新型苯并咪唑化合物

Country Status (2)

Country Link
CN (2) CN113880804A (zh)
WO (1) WO2022002100A1 (zh)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104379575A (zh) * 2012-06-06 2015-02-25 Irm责任有限公司 用于调节egfr活性的化合物和组合物
WO2019162323A1 (en) * 2018-02-21 2019-08-29 Boehringer Ingelheim International Gmbh New benzimidazole compounds and derivatives as egfr inhibitors
WO2020260252A1 (en) * 2019-06-24 2020-12-30 Boehringer Ingelheim International Gmbh New macrocyclic compounds and derivatives as egfr inhibitors

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104379575A (zh) * 2012-06-06 2015-02-25 Irm责任有限公司 用于调节egfr活性的化合物和组合物
WO2019162323A1 (en) * 2018-02-21 2019-08-29 Boehringer Ingelheim International Gmbh New benzimidazole compounds and derivatives as egfr inhibitors
WO2020260252A1 (en) * 2019-06-24 2020-12-30 Boehringer Ingelheim International Gmbh New macrocyclic compounds and derivatives as egfr inhibitors

Also Published As

Publication number Publication date
CN113880804A (zh) 2022-01-04
CN115867542A (zh) 2023-03-28

Similar Documents

Publication Publication Date Title
CN115335379B (zh) 含螺环的喹唑啉化合物
CN113767103B (zh) 新型螺环类K-Ras G12C抑制剂
CN113544128B (zh) Kras-g12c抑制剂
WO2021129824A1 (zh) 新型K-Ras G12C抑制剂
CN115315427B (zh) Hpk1抑制剂及其制备方法和用途
CN116390728B (zh) 喹唑啉衍生物及其制备方法和用途
WO2023061406A1 (zh) 含三并环结构的parp抑制剂、及其制备方法和医药用途
WO2022171088A1 (zh) 吡唑并[3,4-d]嘧啶-3-酮衍生物
WO2023041055A1 (zh) Kif18a抑制剂
WO2022174765A1 (zh) 作为Wee-1抑制剂的稠环化合物
WO2022002100A1 (zh) 新型苯并咪唑化合物
WO2021244505A1 (zh) 新型吡嗪化合物
WO2022012593A1 (zh) 5，6-二氢吡嗪并[2，3-c]异喹啉化合物
WO2022228512A1 (zh) 作为Wee-1抑制剂的吡咯并嘧啶衍生物
WO2022228511A1 (zh) 作为Wee-1抑制剂的稠环化合物及其制备方法和用途
WO2022228509A1 (zh) 吡咯并嘧啶衍生物及其制备方法和用途
WO2022262857A1 (zh) 芳基氧膦类化合物
WO2023134608A1 (zh) 作为hpk1抑制剂的稠环化合物
WO2022171128A1 (zh) 作为Wee-1抑制剂的吡唑并[3,4-d]嘧啶-3-酮衍生物
WO2022171126A1 (zh) 作为Wee-1抑制剂的稠环化合物
WO2023143344A1 (zh) 新型egfr抑制剂
WO2023160614A1 (zh) 作为fak抑制剂的化合物及其用途
WO2023083299A1 (zh) 作为hpk1抑制剂的稠环化合物
WO2023083373A1 (zh) 作为Src抑制剂的化合物
WO2022237844A1 (zh) 含吡嗪结构的吡咯并嘧啶衍生物

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21831682

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 21831682

Country of ref document: EP

Kind code of ref document: A1